




D

TREATMENT
MODALITIES



d treatment modalities

D.1 . 93
Percentages & counts of reported ESRD patients: by treatment modality
incident & point prevalent patients

D.2 . 95
Counts of incident ESRD patients, by initial mode of therapy: all dialysis
by age, gender, race, ethnicity, & primary diagnosis

D.3 . 97
Counts of incident ESRD patients, by initial mode of therapy: hemodialysis
by age, gender, race, ethnicity, & primary diagnosis

D.4 . 99
Counts of incident ESRD patients, by initial mode of therapy: peritoneal dialysis
by age, gender, race, ethnicity, & primary diagnosis

D.5 . 101
Counts of incident ESRD patients, by initial mode of therapy: transplant
by age, gender, race, ethnicity, & primary diagnosis

D.6 . 103
Counts of point prevalent ESRD patients, by mode of therapy: all dialysis
*December 31 point prevalent patients,
by age, gender, race, ethnicity, & primary diagnosis*

D.7 . 105
Counts of point prevalent ESRD patients, by mode of therapy: hemodialysis
*December 31 point prevalent patients,
by age, gender, race, ethnicity, & primary diagnosis*

D.8 . 107
Counts of point prevalent ESRD patients, by mode of therapy: peritoneal dialysis
*December 31 point prevalent patients,
by age, gender, race, ethnicity, & primary diagnosis*

D.9 . 109
Counts of point prevalent ESRD patients, by mode of therapy:
functioning transplant
*December 31 point prevalent patients,
by age, gender, race, ethnicity, & primary diagnosis*

D.10 . 111
Incident ESRD patients, 2004
by age, gender, race, ethnicity, primary diagnosis, & modality

D.11 . 112
Point prevalent ESRD patients, 2004
*December 31 point prevalent patients,
by age, gender, race, ethnicity, primary diagnosis, & modality*

D.12 . 113
Treatment status two years after first ESRD service, 2000-2002
incident patients with Medicare coverage, 2000-2002 combined

D.13 . 114
Point prevalent ESRD patients, 2004: by patient vintage
*December 31 point prevalent patients, by year-end treatment modality
& number of years patient has had ESRD (vintage)*

D.14 . 115
Point prevalent ESRD patients, 2004: by number of years on modality
December 31 point prevalent patients 31, by year-end treatment modality

D.15 . 116
Incident ESRD patients, 2004: by modality & state/territory

D.16 . 117
Point prevalent ESRD patients, 2004: by modality & state/territory
December 31 point prevalent ESRD patients

Table D.1

Percentages & counts of reported ESRD patients: by treatment modality*incident & point prevalent patients*

INCIDENT COUNTS	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992
INCIDENT COUNTS													
Modality													
Dialysis	17,665	19,757	22,156	25,515	27,092	30,036	32,728	36,023	40,253	45,407	49,804	55,058	60,194
Started with a tx	341	326	417	405	467	541	725	903	1,037	1,039	1,093	1,079	1,100
Dialysis type													
Center hemodialysis	15,448	16,770	18,194	20,992	22,227	23,946	26,305	29,050	33,082	37,516	40,889	45,275	49,817
Center self hemodialysis	60	56
Home hemodialysis	161	152	158	182	207	391	372	391	457	530	564	707	831
CAPD	981	1,884	3,141	3,731	3,912	4,032	4,095	4,406	4,678	5,133	5,909	6,134	6,308
CCPD	*	*	*	16	38	137	224	336	312	458	608	832	1,087
Other PD	678	439	265	286	272	586	728	663	719	770	664	770	731
Uncertain dialysis	394	506	391	308	436	944	1,004	1,177	1,005	1,000	1,170	1,280	1,364
All	18,006	20,083	22,573	25,920	27,559	30,577	33,453	36,926	41,290	46,446	50,897	56,137	61,294
PERCENTAGES													
Modality													
Dialysis	98.1	98.4	98.2	98.4	98.3	98.2	97.8	97.6	97.5	97.8	97.9	98.1	98.2
Started with a tx	1.9	1.6	1.8	1.6	1.7	1.8	2.2	2.4	2.5	2.2	2.1	1.9	1.8
Dialysis type													
Center hemodialysis	87.4	84.9	82.1	82.3	82.0	79.7	80.4	80.6	82.2	82.6	82.1	82.2	82.8
Center self hemodialysis	0.1	0.1
Home hemodialysis	0.9	0.8	0.7	0.7	0.8	1.3	1.1	1.1	1.1	1.2	1.1	1.3	1.4
CAPD	5.6	9.5	14.2	14.6	14.4	13.4	12.5	12.2	11.6	11.3	11.9	11.1	10.5
CCPD	.	.	.	0.1	0.1	0.5	0.7	0.9	0.8	1.0	1.2	1.5	1.8
Other PD	3.8	2.2	1.2	1.1	1.0	2.0	2.2	1.8	1.8	1.7	1.3	1.4	1.2
Uncertain dialysis	2.2	2.6	1.8	1.2	1.6	3.1	3.1	3.3	2.5	2.2	2.3	2.3	2.3
All	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
POINT PREVALENT COUNTS													
Modality													
Dialysis	49,935	56,227	63,030	72,937	80,353	86,927	93,619	101,839	111,561	124,119	137,443	152,900	168,822
Functioning graft	10,097	12,652	15,420	18,486	22,162	26,509	31,682	36,539	41,135	45,621	50,572	55,882	61,128
Dialysis type													
Center hemodialysis	44,231	50,326	55,492	62,665	66,544	67,858	73,640	81,393	91,298	102,063	112,783	124,359	137,262
Center self hemodialysis	.	*	*	*	.	*	*	*	*	.	.	681	765
Home hemodialysis	2,025	1,042	897	1,508	2,732	5,823	5,548	4,774	3,193	3,142	2,976	3,212	3,477
CAPD	891	2,604	4,343	6,717	8,754	10,573	11,510	12,429	13,462	15,068	17,005	18,956	20,850
CCPD	*	17	46	72	202	540	791	1,006	1,121	1,345	1,985	2,896	3,696
Other PD	1,424	1,091	1,018	872	780	873	778	695	654	605	497	444	375
Uncertain dialysis	1,360	1,146	1,233	1,102	1,341	1,259	1,351	1,540	1,832	1,896	2,197	2,352	2,397
All	60,032	68,879	78,450	91,423	102,515	113,436	125,301	138,378	152,696	169,740	188,015	208,782	229,950
PERCENTAGES													
Modality													
Dialysis	83.2	81.6	80.3	79.8	78.4	76.6	74.7	73.6	73.1	73.1	73.1	73.2	73.4
Functioning graft	16.8	18.4	19.7	20.2	21.6	23.4	25.3	26.4	26.9	26.9	26.9	26.8	26.6
Dialysis type													
Center hemodialysis	88.6	89.5	88.0	85.9	82.8	78.1	78.7	79.9	81.8	82.2	82.1	81.3	81.3
Center self hemodialysis	0.4	0.5
Home hemodialysis	4.1	1.9	1.4	2.1	3.4	6.7	5.9	4.7	2.9	2.5	2.2	2.1	2.1
CAPD	1.8	4.6	6.9	9.2	10.9	12.2	12.3	12.2	12.1	12.1	12.4	12.4	12.4
CCPD	.	.	0.1	0.1	0.3	0.6	0.8	1.0	1.0	1.1	1.4	1.9	2.2
Other PD	2.9	1.9	1.6	1.2	1.0	1.0	0.8	0.7	0.6	0.5	0.4	0.3	0.2
Uncertain dialysis	2.7	2.0	2.0	1.5	1.7	1.4	1.4	1.5	1.6	1.5	1.6	1.5	1.4
All	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0

The incident cohorts are determined at the time of ESRD initiation without applying the 60-day stable modality rule.

The point prevalent cohorts & associated modalities are determined on December 31 of each calendar year without applying the 60-day stable modality rule.

*Values for cells with ten or fewer patients are suppressed.

. . Zero values in this cell.

Table D.1 (continued)

Percentages & counts of reported ESRD patients: by treatment modality

incident & point prevalent patients

INCIDENT COUNTS	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004
Modality												
Dialysis	63,396	68,845	70,533	76,452	80,849	85,690	89,939	92,190	94,418	98,628	100,838	102,104
Started with a tx	1,079	1,093	1,221	1,305	1,320	1,399	1,584	1,737	1,820	1,946	1,993	2,260
Dialysis type												
Center hemodialysis	52,596	57,547	59,954	65,815	71,658	76,705	80,624	83,612	86,562	91,019	93,245	94,606
Center self hemodialysis	41	24	52	57	48	46	42	30	37	44	39	25
Home hemodialysis	930	969	591	664	338	575	744	293	283	222	261	260
CAPD	6,729	6,747	6,590	6,139	5,630	5,161	4,982	4,660	4,688	4,435	4,569	4,477
CCPD	1,032	1,291	1,974	2,259	2,143	2,239	2,265	2,263	2,320	2,181	2,131	2,209
Other PD	662	622	473	446	416	389	255	302	278	415	290	277
Uncertain dialysis	1,406	1,645	899	1,072	616	575	1,027	1,030	250	312	303	250
All	64,475	69,938	71,754	77,757	82,169	87,089	91,523	93,927	96,238	100,574	102,831	104,364
PERCENTAGES												
Modality												
Dialysis	98.3	98.4	98.3	98.3	98.4	98.4	98.3	98.2	98.1	98.1	98.1	97.8
Started with a tx	1.7	1.6	1.7	1.7	1.6	1.6	1.7	1.8	1.9	1.9	1.9	2.2
Dialysis type												
Center hemodialysis	83.0	83.6	85.0	86.1	88.6	89.5	89.6	90.7	91.7	92.3	92.5	92.7
Center self hemodialysis	0.1	.	0.1	0.1	0.1	0.1
Home hemodialysis	1.5	1.4	0.8	0.9	0.4	0.7	0.8	0.3	0.3	0.2	0.3	0.3
CAPD	10.6	9.8	9.3	8.0	7.0	6.0	5.5	5.1	5.0	4.5	4.5	4.4
CCPD	1.6	1.9	2.8	3.0	2.7	2.6	2.5	2.5	2.5	2.2	2.1	2.2
Other PD	1.0	0.9	0.7	0.6	0.5	0.5	0.3	0.3	0.3	0.4	0.3	0.3
Uncertain dialysis	2.2	2.4	1.3	1.4	0.8	0.7	1.1	1.1	0.3	0.3	0.3	0.2
All	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
POINT PREVALENT COUNTS												
Modality												
Dialysis	183,426	200,307	213,941	229,713	244,947	260,483	275,194	289,238	301,157	313,696	325,002	335,963
Functioning graft	66,637	72,114	77,914	83,812	89,673	96,031	102,139	108,517	115,021	121,864	128,604	136,136
Dialysis type												
Center hemodialysis	149,933	164,357	177,956	194,323	211,714	229,390	244,622	259,705	272,573	285,170	296,112	307,122
Center self hemodialysis	133	195	514	529	466	362	342	271	323	277	196	193
Home hemodialysis	3,850	3,836	3,062	2,949	2,573	2,514	2,415	2,197	1,900	1,779	1,930	1,954
CAPD	22,641	23,784	22,450	20,187	18,082	16,092	14,613	13,373	12,517	11,617	11,296	10,858
CCPD	4,321	5,424	7,844	9,572	10,426	10,601	11,301	11,947	12,773	13,742	14,442	14,907
Other PD	292	278	233	178	139	117	87	77	69	85	62	60
Uncertain dialysis	2,256	2,433	1,882	1,975	1,547	1,407	1,814	1,668	1,002	1,026	964	869
All	250,063	272,421	291,855	313,525	334,620	356,514	377,333	397,755	416,178	435,560	453,606	472,099
PERCENTAGES												
Modality												
Dialysis	73.4	73.5	73.3	73.3	73.2	73.1	72.9	72.7	72.4	72.0	71.6	71.2
Functioning graft	26.6	26.5	26.7	26.7	26.8	26.9	27.1	27.3	27.6	28.0	28.4	28.8
Dialysis type												
Center hemodialysis	81.7	82.1	83.2	84.6	86.4	88.1	88.9	89.8	90.5	90.9	91.1	91.4
Center self hemodialysis	0.1	0.1	0.2	0.2	0.2	0.1	0.1	0.1	0.1	0.1	0.1	0.1
Home hemodialysis	2.1	1.9	1.4	1.3	1.1	1.0	0.9	0.8	0.6	0.6	0.6	0.6
CAPD	12.3	11.9	10.5	8.8	7.4	6.2	5.3	4.6	4.2	3.7	3.5	3.2
CCPD	2.4	2.7	3.7	4.2	4.3	4.1	4.1	4.1	4.2	4.4	4.4	4.4
Other PD	0.2	0.1	0.1	0.1	0.1
Uncertain dialysis	1.2	1.2	0.9	0.9	0.6	0.5	0.7	0.6	0.3	0.3	0.3	0.3
All	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0

The incident cohorts are determined at the time of ESRD initiation without applying the 60-day stable modality rule.

The point prevalent cohorts & associated modalities are determined on December 31 of each calendar year without applying the 60-day stable modality rule.

“. “ Zero values in this cell.

Table D.2

Counts of incident ESRD patients, by initial mode of therapy: all dialysis*by age, gender, race, ethnicity, & primary diagnosis*

	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992
0-4	41	58	83	93	98	123	124	121	116	132	126	160	127
5-9	85	80	87	80	95	80	103	92	83	93	121	86	89
10-14	162	174	210	192	199	186	166	169	179	159	193	199	198
15-19	409	451	426	415	396	405	403	416	458	465	478	436	491
20-29	1,451	1,618	1,810	1,770	1,919	1,963	2,026	2,033	2,208	2,366	2,462	2,491	2,640
30-39	2,136	2,385	2,657	2,734	2,945	3,174	3,456	3,597	4,020	4,387	4,602	4,852	5,210
40-49	2,375	2,690	2,806	3,165	3,302	3,601	3,869	4,347	4,820	5,477	6,021	6,720	7,273
50-59	3,726	4,338	4,635	4,815	5,068	5,452	5,733	6,157	7,065	7,603	8,221	8,881	9,818
60-64	2,134	2,455	2,787	3,208	3,529	3,949	4,124	4,589	5,042	5,500	6,108	6,661	6,986
65-69	2,184	2,271	2,602	3,332	3,514	3,921	4,449	5,102	5,660	6,530	7,236	8,011	8,631
70-79	2,529	2,749	3,401	4,685	4,922	5,789	6,598	7,452	8,310	9,782	10,873	12,692	14,188
80+	433	486	648	1,019	1,097	1,380	1,668	1,943	2,290	2,906	3,360	3,868	4,542
Unknown	.	*	*	*	*	13	*	*	*	*	*	*	*
0-19	697	763	806	780	788	794	796	798	836	849	918	881	905
20-44	4,668	5,274	5,775	5,979	6,385	6,823	7,315	7,723	8,533	9,305	10,025	10,586	11,315
45-64	7,154	8,212	8,920	9,713	10,378	11,316	11,893	13,000	14,622	16,028	17,389	19,019	20,612
65-74	3,789	4,017	4,760	6,202	6,447	7,410	8,275	9,468	10,434	12,046	13,501	15,297	16,793
75+	1,357	1,489	1,891	2,834	3,086	3,680	4,440	5,029	5,826	7,172	7,968	9,274	10,568
Unknown	.	*	*	*	*	13	*	*	*	*	*	*	*
Male	9,814	10,898	12,160	13,958	14,914	16,271	17,828	19,455	21,533	24,416	26,697	29,342	31,826
Female	7,851	8,859	9,996	11,556	12,178	13,765	14,900	16,568	18,720	20,991	23,107	25,716	28,368
Unknown	.	.	.	*
White	12,319	13,727	15,426	17,357	18,428	20,392	22,251	24,218	26,649	29,986	32,952	36,263	39,389
Black	4,822	5,448	6,128	7,419	7,830	8,677	9,332	10,536	12,022	13,813	14,886	16,609	18,261
Native American	121	146	192	270	279	293	375	427	506	545	585	626	750
Asian	107	174	339	366	478	592	657	755	909	975	1,259	1,433	1,616
Other/unknown	296	262	71	103	77	82	113	87	167	88	122	127	178
†Hispanic													
†Non-Hispanic													
Diabetes	2,649	3,987	5,221	6,153	7,416	8,597	9,925	11,308	12,869	15,510	17,915	20,469	22,757
Hypertension	3,128	4,517	5,820	6,345	7,168	8,231	8,926	10,313	11,913	13,901	15,321	17,018	19,031
Glomerulonephritis	2,761	3,604	4,221	4,442	4,755	4,999	5,251	5,696	6,108	6,446	6,872	7,101	7,261
Cystic kidney	773	933	1,074	1,091	1,133	1,207	1,274	1,298	1,339	1,351	1,489	1,533	1,644
Other urologic	460	665	853	959	966	1,168	1,176	1,290	1,342	1,350	1,283	1,455	1,529
Other cause	1,768	2,157	2,724	3,004	3,189	3,461	3,529	3,543	3,853	4,496	4,667	5,089	5,529
Unknown cause	1,590	1,654	1,362	1,403	1,439	1,508	1,756	1,928	2,002	1,782	1,880	2,062	2,177
Missing cause	4,536	2,240	881	2,118	1,026	865	891	647	827	571	377	331	266
All	17,665	19,757	22,156	25,515	27,092	30,036	32,728	36,023	40,253	45,407	49,804	55,058	60,194

The incident cohorts are determined at the time of ESRD initiation without applying the 60-day stable modality rule.

The age of the incident patient is determined as of the date of ESRD initiation.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

*Values for cells with ten or fewer patients are suppressed.

“.” Zero values in this cell.

d treatment modalities

Table D.2 (continued)

Counts of incident ESRD patients, by initial mode of therapy: all dialysis

by age, gender, race, ethnicity, & primary diagnosis

	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004
0-4	154	130	149	147	146	154	146	167	170	161	168	207
5-9	107	127	111	111	95	103	121	120	119	128	103	122
10-14	199	223	217	224	232	216	239	247	248	292	291	277
15-19	469	459	493	505	465	491	527	504	500	506	541	551
20-29	2,686	2,672	2,569	2,573	2,520	2,590	2,482	2,543	2,540	2,449	2,389	2,443
30-39	5,332	5,644	5,479	5,595	5,527	5,514	5,685	5,495	5,452	5,484	5,468	5,463
40-49	7,773	8,204	8,748	9,344	9,396	10,151	10,317	10,537	10,548	10,883	11,178	11,391
50-59	10,413	11,713	11,867	12,521	13,587	14,798	15,959	16,404	17,248	17,794	18,620	19,164
60-64	7,349	7,793	8,059	8,455	8,904	9,450	9,643	9,935	10,290	10,497	11,119	11,404
65-69	8,959	9,609	9,601	10,428	10,821	11,100	11,195	11,361	11,588	11,843	12,130	12,025
70-79	14,998	16,626	17,125	19,333	20,781	21,884	23,218	23,681	23,983	25,089	24,961	24,661
80+	4,957	5,641	6,111	7,216	8,374	9,238	10,407	11,196	11,732	13,501	13,870	14,393
Unknown	.	*	*	.	*	*	.	.	.	*	.	*
0-19	929	939	970	987	938	964	1,033	1,038	1,037	1,087	1,103	1,157
20-44	11,602	11,967	12,022	12,338	12,142	12,551	12,573	12,552	12,467	12,468	12,520	12,621
45-64	21,951	24,059	24,700	26,150	27,792	29,952	31,513	32,362	33,611	34,639	36,254	37,244
65-74	17,590	19,128	19,290	21,259	22,169	22,798	23,241	23,625	24,015	24,623	24,578	24,422
75+	11,324	12,748	13,547	15,718	17,807	19,424	21,579	22,613	23,288	25,810	26,383	26,657
Unknown	.	*	*	.	*	*	.	.	.	*	.	*
Male	33,724	36,432	37,145	40,734	42,985	45,581	48,030	49,252	50,737	53,502	54,617	56,279
Female	29,672	32,413	33,384	35,718	37,864	40,109	41,906	42,937	43,681	45,126	46,213	45,791
Unknown	.	.	*	.	.	.	*	*	.	.	*	34
White	41,007	44,405	44,745	48,889	52,019	54,712	58,130	59,848	61,066	63,759	64,881	66,023
Black	19,497	21,107	21,684	22,960	24,077	25,784	26,261	26,503	27,427	28,648	29,356	28,846
Native American	759	829	872	934	950	1,061	1,142	1,190	1,140	1,139	1,109	1,163
Asian	1,924	2,168	2,296	2,499	2,621	2,940	3,187	3,148	3,337	3,531	3,635	3,664
Other/unknown	209	336	936	1,170	1,182	1,193	1,219	1,501	1,448	1,551	1,857	2,408
†Hispanic				8,811	9,079	9,675	10,651	12,348	11,595	12,449	13,199	13,396
†Non-Hispanic				67,641	71,770	76,015	79,288	79,842	82,823	86,179	87,639	88,708
Diabetes	24,382	27,181	29,648	33,140	35,697	38,085	40,080	41,799	42,931	44,338	45,205	45,456
Hypertension	19,758	21,409	19,173	20,310	21,821	23,012	24,377	24,785	25,662	27,188	28,280	27,940
Glomerulonephritis	7,562	8,155	8,153	8,547	8,510	8,655	8,639	8,314	8,186	8,359	8,063	8,094
Cystic kidney	1,711	1,788	1,816	1,749	1,868	1,967	2,024	1,971	2,002	1,981	1,993	2,001
Other urologic	1,349	1,395	2,006	2,259	2,310	2,353	2,762	2,589	2,628	2,819	2,716	2,708
Other cause	5,954	6,435	7,061	7,362	7,534	8,188	8,500	8,812	8,937	9,726	9,931	10,392
Unknown cause	2,269	2,306	2,506	2,922	2,978	3,257	3,367	3,715	3,910	3,921	4,110	3,959
Missing cause	411	176	170	163	131	173	190	205	162	296	540	1,554
All	63,396	68,845	70,533	76,452	80,849	85,690	89,939	92,190	94,418	98,628	100,838	102,104

The incident cohorts are determined at the time of ESRD initiation without applying the 60-day stable modality rule.

The age of the incident patient is determined as of the date of ESRD initiation.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

*Values for cells with ten or fewer patients are suppressed.

." Zero values in this cell.

Table D.3

Counts of incident ESRD patients, by initial mode of therapy: hemodialysis*by age, gender, race, ethnicity, & primary diagnosis*

	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992
0-4	22	18	22	26	20	32	37	21	23	37	35	35	21
5-9	58	47	49	34	35	29	30	33	27	30	50	31	36
10-14	134	127	118	110	97	100	85	88	87	85	92	81	105
15-19	377	394	343	325	301	299	295	291	337	344	338	329	338
20-29	1,297	1,399	1,530	1,469	1,560	1,614	1,620	1,595	1,733	1,888	1,894	1,970	2,099
30-39	1,850	2,017	2,157	2,163	2,371	2,475	2,689	2,788	3,150	3,405	3,539	3,694	4,039
40-49	2,099	2,356	2,289	2,567	2,673	2,856	3,053	3,449	3,882	4,326	4,764	5,231	5,758
50-59	3,283	3,729	3,880	3,970	4,168	4,435	4,698	5,034	5,911	6,261	6,716	7,300	8,023
60-64	1,924	2,087	2,340	2,689	2,970	3,242	3,427	3,820	4,258	4,673	5,115	5,574	5,865
65-69	1,970	1,951	2,205	2,901	2,994	3,226	3,720	4,283	4,871	5,671	6,227	6,963	7,597
70-79	2,223	2,389	2,871	4,043	4,300	4,861	5,605	6,345	7,237	8,686	9,643	11,286	12,654
80+	372	407	545	871	939	1,157	1,410	1,690	2,021	2,635	3,037	3,547	4,169
Unknown	.	*	*	*	*	11	*	*	*	*	*	*	.
0-19	591	586	532	495	453	460	447	433	474	496	515	476	500
20-44	4,106	4,521	4,742	4,817	5,160	5,424	5,740	6,011	6,728	7,297	7,753	8,135	8,864
45-64	6,347	7,067	7,454	8,041	8,582	9,198	9,747	10,675	12,206	13,256	14,275	15,634	16,920
65-74	3,379	3,454	4,025	5,371	5,529	6,163	6,961	7,973	9,000	10,559	11,733	13,406	14,826
75+	1,186	1,293	1,596	2,444	2,704	3,081	3,774	4,345	5,129	6,433	7,174	8,390	9,594
Unknown	.	*	*	*	*	11	*	*	*	*	*	*	.
Male	8,750	9,455	10,163	11,662	12,347	13,249	14,559	15,898	17,958	20,399	22,229	24,387	26,724
Female	6,859	7,467	8,189	9,511	10,087	11,088	12,118	13,543	15,581	17,647	19,224	21,655	23,980
Unknown	.	.	.	*
White	10,754	11,567	12,582	14,163	15,018	16,119	17,776	19,372	21,717	24,632	26,842	29,647	32,482
Black	4,393	4,830	5,238	6,374	6,724	7,387	7,925	8,976	10,440	12,034	12,904	14,506	16,041
Native American	107	133	167	226	224	248	310	365	433	471	499	533	632
Asian	99	158	302	325	407	523	583	667	820	840	1,126	1,267	1,409
Other/unknown	256	234	63	86	61	60	83	61	129	69	82	89	140
†Hispanic													
†Non-Hispanic													
Diabetes	2,199	3,272	4,111	4,879	5,962	6,825	7,984	9,128	10,668	12,911	14,841	16,993	19,016
Hypertension	2,759	3,944	4,911	5,389	6,167	6,912	7,549	8,808	10,280	12,085	13,248	14,856	16,767
Glomerulonephritis	2,414	3,128	3,515	3,694	3,908	4,016	4,226	4,541	4,906	5,186	5,476	5,665	5,769
Cystic kidney	701	790	918	922	929	991	1,025	1,034	1,068	1,068	1,143	1,147	1,249
Other urologic	402	577	712	809	814	953	995	1,099	1,171	1,188	1,099	1,279	1,309
Other cause	1,553	1,864	2,295	2,465	2,618	2,769	2,852	2,808	3,182	3,708	3,820	4,127	4,552
Unknown cause	1,405	1,350	1,118	1,132	1,166	1,207	1,370	1,555	1,644	1,473	1,542	1,728	1,848
Missing cause	4,176	1,997	772	1,884	870	664	676	468	620	427	284	247	194
All	15,609	16,922	18,352	21,174	22,434	24,337	26,677	29,441	33,539	38,046	41,453	46,042	50,704

The incident cohorts are determined at the time of ESRD initiation without applying the 60-day stable modality rule.

The age of the incident patient is determined as of the date of ESRD initiation.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

*Values for cells with ten or fewer patients are suppressed.

“.” Zero values in this cell.

d treatment modalities

Table D.3 (continued)

Counts of incident ESRD patients, by initial mode of therapy: hemodialysis

by age, gender, race, ethnicity, & primary diagnosis

	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004
0-4	38	26	38	24	38	30	33	42	46	39	41	50
5-9	36	50	49	39	33	44	45	52	56	59	44	58
10-14	101	112	111	103	117	113	128	136	146	173	164	149
15-19	333	334	356	374	341	379	422	390	393	412	438	431
20-29	2,119	2,155	2,103	2,124	2,124	2,234	2,164	2,220	2,250	2,206	2,149	2,183
30-39	4,151	4,424	4,397	4,608	4,681	4,714	4,913	4,826	4,809	4,840	4,875	4,869
40-49	6,135	6,621	7,069	7,788	8,046	8,880	9,057	9,347	9,427	9,894	10,130	10,359
50-59	8,641	9,689	9,963	10,688	11,785	13,055	14,261	14,775	15,540	16,197	17,026	17,584
60-64	6,239	6,596	6,886	7,435	7,970	8,573	8,740	9,060	9,485	9,683	10,310	10,629
65-69	7,809	8,459	8,431	9,264	9,852	10,158	10,254	10,393	10,811	11,034	11,301	11,241
70-79	13,433	14,902	15,522	17,422	19,171	20,359	21,543	22,054	22,673	23,759	23,698	23,443
80+	4,532	5,169	5,669	6,667	7,885	8,786	9,850	10,640	11,246	12,989	13,369	13,892
Unknown	.	*	*	.	*	*	*
0-19	508	522	554	540	529	566	628	620	641	683	687	688
20-44	9,060	9,507	9,734	10,193	10,271	10,851	10,932	11,024	11,033	11,183	11,248	11,290
45-64	18,225	19,978	20,684	22,450	24,335	26,605	28,203	29,204	30,478	31,637	33,242	34,334
65-74	15,479	16,917	17,174	18,936	20,276	20,977	21,332	21,767	22,508	23,103	23,051	22,936
75+	10,295	11,613	12,448	14,417	16,632	18,326	20,315	21,320	22,222	24,679	25,317	25,640
Unknown	.	*	*	.	*	*	*
Male	28,470	30,913	31,834	35,463	38,351	41,231	43,537	44,931	46,781	49,574	50,706	52,357
Female	25,097	27,627	28,760	31,073	33,693	36,095	37,871	39,004	40,101	41,711	42,832	42,503
Unknown	.	.	*	.	.	.	*	.	.	.	*	31
White	33,982	37,035	37,715	41,636	45,568	48,633	51,806	53,799	55,611	58,512	59,705	60,875
Black	17,099	18,664	19,360	20,881	22,241	24,031	24,544	24,856	25,860	27,090	27,779	27,383
Native American	660	710	750	825	858	954	1,059	1,067	1,049	1,047	1,035	1,093
Asian	1,658	1,849	1,951	2,166	2,311	2,623	2,896	2,840	3,029	3,208	3,307	3,356
Other/unknown	168	282	821	1,028	1,066	1,085	1,105	1,373	1,333	1,428	1,719	2,184
†Hispanic				7,813	8,234	8,826	9,777	11,382	10,817	11,573	12,358	12,566
†Non-Hispanic				58,723	63,810	68,500	71,633	72,553	76,065	79,712	81,187	82,325
Diabetes	20,587	23,054	25,401	28,732	31,835	34,394	36,307	38,150	39,744	41,164	42,136	42,590
Hypertension	17,335	18,926	17,076	18,355	20,038	21,316	22,606	23,058	24,111	25,616	26,669	26,348
Glomerulonephritis	6,075	6,519	6,594	7,005	7,146	7,370	7,465	7,137	7,104	7,369	7,057	7,021
Cystic kidney	1,287	1,349	1,382	1,347	1,475	1,606	1,631	1,609	1,617	1,646	1,627	1,652
Other urologic	1,151	1,183	1,731	1,998	2,064	2,141	2,524	2,345	2,410	2,605	2,512	2,497
Other cause	4,903	5,416	6,070	6,395	6,717	7,361	7,655	8,045	8,134	8,991	9,193	9,654
Unknown cause	1,923	1,972	2,211	2,576	2,669	3,002	3,070	3,433	3,625	3,670	3,875	3,720
Missing cause	306	121	132	128	100	136	152	158	137	224	476	1,409
All	53,567	58,540	60,597	66,536	72,044	77,326	81,410	83,935	86,882	91,285	93,545	94,891

The incident cohorts are determined at the time of ESRD initiation without applying the 60-day stable modality rule.

The age of the incident patient is determined as of the date of ESRD initiation.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

*Values for cells with ten or fewer patients are suppressed.

“. . .” Zero values in this cell.

Table D.4

Counts of incident ESRD patients, by initial mode of therapy: peritoneal dialysis*by age, gender, race, ethnicity, & primary diagnosis*

	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992
0-4	*	28	50	57	67	83	77	85	82	69	73	98	88
5-9	15	22	34	41	54	44	62	50	45	53	52	43	45
10-14	13	29	74	73	91	72	73	73	81	56	84	87	80
15-19	15	31	63	73	76	84	83	99	81	106	107	84	128
20-29	73	143	220	250	300	274	330	322	377	358	442	409	431
30-39	139	241	415	501	486	558	590	628	689	789	852	967	980
40-49	152	232	431	529	544	587	640	695	760	897	1,028	1,234	1,245
50-59	240	439	628	749	790	794	812	882	890	1,060	1,192	1,269	1,444
60-64	107	240	366	455	476	550	512	571	608	624	790	829	873
65-69	84	212	327	372	424	431	458	526	512	608	761	761	744
70-79	118	224	451	530	517	572	542	659	698	773	910	986	1,083
80+	19	49	88	116	123	120	140	151	167	196	226	199	253
Unknown	.	.	*	*	*	.	.	*	.	*	.	.	*
0-19	52	110	221	244	288	283	295	307	289	284	316	312	341
20-44	282	501	846	1,005	1,037	1,099	1,233	1,307	1,441	1,573	1,814	2,023	2,026
45-64	429	794	1,214	1,479	1,559	1,664	1,651	1,791	1,883	2,155	2,490	2,685	2,947
65-74	162	367	611	701	753	779	784	939	943	1,053	1,331	1,359	1,401
75+	59	118	255	317	311	344	356	397	434	524	566	587	679
Unknown	.	.	*	*	*	.	.	*	.	*	.	.	*
Male	515	942	1,654	1,994	2,163	2,210	2,374	2,532	2,680	3,020	3,504	3,823	3,965
Female	469	948	1,494	1,753	1,787	1,959	1,945	2,210	2,310	2,571	3,013	3,143	3,430
Unknown
White	791	1,462	2,350	2,768	2,930	3,193	3,264	3,564	3,755	4,117	4,850	5,123	5,402
Black	159	401	751	905	916	877	935	1,064	1,088	1,310	1,479	1,616	1,707
Native American	11	*	18	41	46	41	57	52	67	61	74	77	90
Asian	*	*	27	27	53	49	53	57	71	99	103	133	174
Other/unknown	16	*	*	*	*	*	*	*	*	*	11	17	22
†Hispanic													
†Non-Hispanic													
Diabetes	255	528	951	1,134	1,249	1,345	1,455	1,650	1,677	2,049	2,424	2,724	2,977
Hypertension	215	402	794	846	850	918	925	998	1,189	1,320	1,623	1,631	1,700
Glomerulonephritis	206	347	584	655	729	773	796	868	949	1,007	1,119	1,193	1,243
Cystic kidney	46	104	132	148	179	173	198	209	217	230	282	321	334
Other urologic	24	62	112	125	120	139	120	125	120	105	133	128	147
Other cause	134	209	353	481	502	531	498	566	505	595	663	703	741
Unknown cause	88	186	190	204	208	183	224	207	203	192	225	224	229
Missing cause	16	52	32	154	113	107	103	119	130	93	48	42	24
All	984	1,890	3,148	3,747	3,950	4,169	4,319	4,742	4,990	5,591	6,517	6,966	7,395

The incident cohorts are determined at the time of ESRD initiation without applying the 60-day stable modality rule.

The age of the incident patient is determined as of the date of ESRD initiation.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

*Values for cells with ten or fewer patients are suppressed.

“ . ” Zero values in this cell.



Table D.4 (continued)

Counts of incident ESRD patients, by initial mode of therapy: peritoneal dialysis

by age, gender, race, ethnicity, & primary diagnosis

	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004
0-4	98	85	101	115	104	121	109	122	120	116	123	149
5-9	54	70	61	68	59	55	73	65	62	66	53	62
10-14	82	97	99	112	109	98	105	106	98	118	124	125
15-19	111	105	125	125	118	107	101	106	101	88	99	113
20-29	463	430	423	419	366	340	298	295	270	222	233	255
30-39	970	1,006	996	931	800	755	734	643	611	603	573	568
40-49	1,355	1,312	1,541	1,476	1,262	1,199	1,175	1,117	1,065	940	997	987
50-59	1,488	1,643	1,734	1,687	1,715	1,623	1,573	1,494	1,639	1,507	1,508	1,512
60-64	864	928	1,021	936	870	807	812	796	769	758	765	738
65-69	866	826	933	857	775	779	726	727	708	694	749	698
70-79	1,129	1,217	1,209	1,331	1,245	1,179	1,181	1,119	1,147	1,099	1,068	1,064
80+	281	319	320	341	350	337	360	333	418	404	408	415
Unknown	.	.	*	*	.	.
0-19	345	357	386	420	390	381	388	399	381	388	399	449
20-44	2,076	2,047	2,094	2,023	1,758	1,605	1,547	1,447	1,361	1,202	1,220	1,283
45-64	3,064	3,272	3,621	3,426	3,255	3,119	3,045	2,898	2,993	2,828	2,856	2,777
65-74	1,561	1,592	1,657	1,692	1,498	1,476	1,415	1,356	1,358	1,295	1,354	1,313
75+	715	770	805	837	872	819	852	823	915	902	871	864
Unknown	.	.	*	*	.	.
Male	4,102	4,255	4,550	4,452	4,086	3,852	3,796	3,675	3,660	3,525	3,579	3,646
Female	3,659	3,783	4,014	3,946	3,687	3,548	3,451	3,248	3,348	3,091	3,121	3,039
Unknown	*
White	5,577	5,717	6,065	6,057	5,705	5,382	5,373	5,049	5,070	4,736	4,710	4,747
Black	1,865	1,904	1,986	1,809	1,602	1,552	1,469	1,404	1,450	1,400	1,478	1,388
Native American	82	98	106	100	80	84	73	102	84	72	69	64
Asian	222	290	316	311	283	286	245	264	300	311	318	287
Other/unknown	15	29	91	121	103	96	87	104	104	97	125	200
†Hispanic				895	788	773	802	879	741	818	778	765
†Non-Hispanic				7,503	6,985	6,627	6,445	6,044	6,267	5,798	5,922	5,921
Diabetes	3,051	3,262	3,682	3,767	3,444	3,255	3,228	3,052	2,996	2,879	2,824	2,674
Hypertension	1,867	1,878	1,725	1,533	1,493	1,458	1,408	1,370	1,415	1,398	1,472	1,477
Glomerulonephritis	1,232	1,345	1,435	1,398	1,282	1,201	1,085	1,076	1,042	929	959	1,037
Cystic kidney	379	380	390	367	360	338	366	332	360	323	351	332
Other urologic	153	139	214	200	206	181	192	196	201	195	176	188
Other cause	802	779	853	827	721	734	725	663	734	660	667	675
Unknown cause	244	235	249	292	257	224	232	225	252	210	221	223
Missing cause	33	20	16	14	*	*	11	*	*	22	30	80
All	7,761	8,038	8,564	8,398	7,773	7,400	7,247	6,923	7,008	6,616	6,700	6,686

The incident cohorts are determined at the time of ESRD initiation without applying the 60-day stable modality rule.

The age of the incident patient is determined as of the date of ESRD initiation.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

*Values for cells with ten or fewer patients are suppressed.

“. .” Zero values in this cell.

Table D.5

Counts of incident ESRD patients, by initial mode of therapy: transplant*by age, gender, race, ethnicity, & primary diagnosis*

	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992
0-4	*	11	18	12	14	16	11	25	27	25	24	21	26
5-9	11	17	18	*	15	23	19	23	22	35	33	41	37
10-14	18	14	14	20	31	29	44	51	46	48	53	49	50
15-19	24	25	31	28	36	37	54	65	63	63	67	53	41
20-29	88	73	90	85	87	125	130	154	213	214	175	161	153
30-39	89	98	107	116	130	134	220	242	277	267	288	297	291
40-49	69	50	80	84	83	98	134	174	198	220	257	277	269
50-59	29	31	55	40	55	54	78	124	146	120	141	130	167
60-64	*	*	*	*	*	*	18	29	29	29	33	35	41
65-69	*	*	.	*	*	*	*	*	*	12	15	12	18
70-79	.	*	.	*	*	*	*	*	*	*	*	*	*
80+	*	*	*	.	*	*	*	*	.	*	*	.	*
Unknown	*
0-19	59	67	81	69	96	105	128	164	158	171	177	164	154
20-44	209	198	241	244	265	321	422	492	604	602	621	628	598
45-64	69	58	94	89	93	98	158	231	259	248	273	272	323
65-74	*	*	.	*	*	11	13	12	15	16	20	14	23
75+	*	*	*	.	*	*	*	*	*	*	*	*	*
Unknown	*
Male	223	220	271	256	297	314	434	530	618	606	636	637	611
Female	118	105	146	149	169	227	291	373	419	433	457	442	489
Unknown	.	*	.	.	*
White	263	257	319	298	363	433	604	719	796	877	900	944	941
Black	53	51	67	55	60	57	75	114	137	110	119	92	112
Native American	.	*	*	*	*	*	*	*	11	*	*	*	*
Asian	*	*	11	13	*	11	*	27	31	25	34	19	28
Other/unknown	23	14	19	31	30	31	31	38	62	25	30	14	*
†Hispanic													
†Non-Hispanic													
Diabetes	38	59	88	70	100	116	179	191	210	257	237	271	235
Hypertension	29	25	39	34	26	31	45	76	82	59	70	70	103
Glomerulonephritis	55	56	79	86	92	122	123	180	161	194	222	196	226
Cystic kidney	*	13	*	20	19	26	45	72	68	77	96	99	100
Other urologic	24	25	14	22	28	25	45	45	42	62	55	64	41
Other cause	46	38	53	44	73	66	95	115	109	136	146	143	160
Unknown cause	18	15	42	43	39	60	57	65	75	61	78	80	82
Missing cause	129	95	94	86	90	95	136	159	290	193	189	156	153
All	341	326	417	405	467	541	725	903	1,037	1,039	1,093	1,079	1,100

The incident cohorts are determined at the time of ESRD initiation without applying the 60-day stable modality rule.

The age of the incident patient is determined as of the date of ESRD initiation.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

*Values for cells with ten or fewer patients are suppressed.

“.” Zero values in this cell.

Table D.5 (continued)

Counts of incident ESRD patients, by initial mode of therapy: transplant

by age, gender, race, ethnicity, & primary diagnosis

	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004
0-4	31	16	19	38	31	20	34	29	34	20	33	41
5-9	27	35	35	33	37	32	34	34	32	52	45	31
10-14	44	35	63	46	50	55	60	64	62	50	48	44
15-19	61	70	75	76	68	53	82	72	82	77	84	93
20-29	143	152	133	139	141	149	169	157	167	149	156	183
30-39	269	276	311	279	270	315	279	315	295	328	277	313
40-49	246	272	286	362	323	368	418	443	458	474	466	513
50-59	175	160	198	227	263	286	332	399	442	493	534	608
60-64	50	47	57	73	82	66	87	117	130	161	169	208
65-69	21	20	30	26	47	45	57	69	82	94	128	143
70-79	11	*	13	*	*	*	30	37	35	48	51	81
80+	*	*	*	*	.	*	*
Unknown	*	.	*	.	.	.	*
0-19	163	156	192	193	186	160	210	199	210	199	210	209
20-44	548	568	584	610	579	647	652	697	679	696	632	726
45-64	335	339	401	470	500	537	633	734	813	909	970	1,099
65-74	29	28	41	31	52	51	86	104	110	133	171	212
75+	*	*	*	*	*	*	*	*	*	*	*	14
Unknown	*	.	*	.	.	.	*
Male	626	607	686	781	789	794	912	992	1,046	1,103	1,140	1,274
Female	453	485	533	524	531	605	672	745	774	843	852	986
Unknown	.	*	*	*	.
White	950	882	945	1,024	1,137	1,247	1,392	1,495	1,591	1,671	1,689	1,764
Black	91	168	219	219	125	97	133	143	139	180	192	187
Native American	*	*	*	12	11	*	*	11	*	*	13	*
Asian	23	30	30	40	30	31	30	52	51	64	59	50
Other/unknown	*	*	17	*	17	14	22	36	29	22	40	251
†Hispanic				78	78	96	96	118	112	132	140	137
†Non-Hispanic				1,227	1,242	1,303	1,488	1,619	1,708	1,814	1,853	2,123
Diabetes	259	252	279	318	292	283	311	290	366	390	368	415
Hypertension	74	82	72	65	88	77	87	110	137	178	167	192
Glomerulonephritis	202	200	253	262	244	271	295	328	341	378	357	396
Cystic kidney	99	87	128	147	123	190	169	217	248	270	305	294
Other urologic	59	61	103	83	109	78	74	116	106	142	125	129
Other cause	163	163	183	191	205	200	206	229	291	293	291	313
Unknown cause	116	92	62	77	108	69	132	100	115	135	97	96
Missing cause	107	156	141	162	151	231	310	347	216	160	283	425
All	1,079	1,093	1,221	1,305	1,320	1,399	1,584	1,737	1,820	1,946	1,993	2,260

The incident cohorts are determined at the time of ESRD initiation without applying the 60-day stable modality rule. The age of the incident patient is determined as of the date of ESRD initiation.
 †CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.
 *Values for cells with ten or fewer patients are suppressed.
 ". ." Zero values in this cell.

Table D.6

Counts of point prevalent ESRD patients, by mode of therapy: all dialysis*December 31 point prevalent patients, by age, gender, race, ethnicity, & primary diagnosis*

	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992
0-4	42	65	93	118	133	164	178	172	169	182	181	205	201
5-9	113	107	132	157	165	136	160	166	174	192	204	178	182
10-14	273	296	332	368	354	328	321	342	364	349	392	407	414
15-19	846	859	902	849	843	886	853	884	957	1,031	1,025	1,048	1,094
20-29	4,053	4,305	4,642	4,993	5,233	5,364	5,427	5,588	5,976	6,428	6,768	6,994	7,414
30-39	6,431	7,167	7,977	8,785	9,596	10,228	10,773	11,383	12,248	13,442	14,391	15,527	16,708
40-49	7,877	8,574	9,309	10,756	11,605	12,177	12,807	13,800	15,304	17,284	19,292	21,660	23,794
50-59	11,850	13,257	14,591	15,901	16,971	17,840	18,576	19,352	20,797	22,536	24,549	27,016	29,824
60-64	6,099	7,272	8,289	9,738	10,856	11,809	12,370	13,470	14,387	15,561	16,989	18,299	19,628
65-69	5,524	6,211	7,041	8,605	9,745	10,846	12,248	13,861	15,292	17,088	18,913	20,895	23,002
70-79	5,950	7,006	8,314	10,632	12,398	14,109	16,183	18,277	20,526	23,577	26,914	31,401	35,562
80+	874	1,103	1,401	2,022	2,437	3,021	3,708	4,536	5,361	6,443	7,819	9,266	10,999
Unknown	*	*	*	13	17	19	15	*	*	*	*	*	.
0-19	1,274	1,327	1,459	1,492	1,495	1,514	1,512	1,564	1,664	1,754	1,802	1,838	1,891
20-44	14,159	15,405	16,924	18,829	20,228	21,274	22,339	23,525	25,539	28,141	30,665	33,005	35,499
45-64	22,151	25,170	27,884	31,344	34,033	36,144	37,614	40,068	43,173	47,110	51,324	56,491	61,869
65-74	9,448	10,746	12,405	15,286	17,387	19,422	21,993	24,702	27,361	30,839	34,764	39,431	43,987
75+	2,900	3,574	4,351	5,973	7,193	8,554	10,146	11,972	13,818	16,269	18,882	22,131	25,576
Unknown	*	*	*	13	17	19	15	*	*	*	*	*	.
Male	27,178	30,231	33,776	38,859	42,777	45,881	48,977	52,888	57,680	64,178	71,130	79,245	87,328
Female	22,757	25,996	29,254	34,077	37,576	41,046	44,642	48,951	53,881	59,941	66,313	73,655	81,494
Unknown	.	.	.	*
White	33,565	37,268	41,362	47,280	51,365	54,976	58,546	62,894	67,907	74,698	81,971	90,470	98,859
Black	15,039	17,387	19,907	23,580	26,625	29,225	31,976	35,408	39,534	44,737	50,072	56,122	62,614
Native American	282	380	474	635	754	862	999	1,157	1,330	1,510	1,699	1,918	2,227
Asian	319	448	668	898	1,140	1,455	1,717	2,039	2,444	2,913	3,436	4,108	4,782
Other/unknown	730	744	619	544	469	409	381	341	346	261	265	282	340
†Hispanic													
†Non-Hispanic													
Diabetes	4,905	6,815	9,145	11,578	14,424	17,097	19,971	23,340	27,268	32,742	38,812	45,766	53,032
Hypertension	8,541	10,975	13,945	16,955	19,746	22,310	25,113	28,224	31,860	36,589	41,224	46,598	52,316
Glomerulonephritis	10,208	11,636	13,259	15,263	16,793	18,053	19,101	20,294	21,547	23,150	24,605	26,172	27,660
Cystic kidney	3,226	3,655	4,146	4,707	5,047	5,345	5,500	5,687	5,818	5,987	6,203	6,504	6,752
Other urologic	1,227	1,547	1,955	2,372	2,753	3,138	3,365	3,690	3,991	4,226	4,370	4,672	4,936
Other cause	4,968	5,786	6,981	8,245	9,214	10,094	10,717	11,277	12,166	13,448	14,463	15,475	16,650
Unknown cause	5,354	5,656	5,544	5,886	6,084	5,978	6,108	6,361	6,430	6,154	6,233	6,481	6,633
Missing cause	11,506	10,157	8,055	7,931	6,292	4,912	3,744	2,966	2,481	1,823	1,533	1,232	843
All	49,935	56,227	63,030	72,937	80,353	86,927	93,619	101,839	111,561	124,119	137,443	152,900	168,822

The point prevalent cohorts are determined on December 31 of each calendar year without applying the 60-day stable modality rule.

The age of the point prevalent patient is determined as of December 31 of each calendar year.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

*Values for cells with ten or fewer patients are suppressed.

“.” Zero values in this cell.

Table D.6 (continued)

Counts of point prevalent ESRD patients, by mode of therapy: all dialysis

December 31 point prevalent patients, by age, gender, race, ethnicity, & primary diagnosis

	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004
0-4	220	218	234	232	206	216	214	244	229	227	238	287
5-9	187	226	217	218	227	216	215	243	236	238	218	237
10-14	421	444	441	429	433	459	434	498	525	567	529	531
15-19	1,129	1,082	1,109	1,160	1,174	1,205	1,197	1,146	1,195	1,249	1,274	1,310
20-29	7,690	8,018	8,184	8,430	8,614	8,896	8,972	9,073	9,085	8,985	8,943	9,051
30-39	17,792	18,889	19,380	19,908	20,412	20,796	21,492	21,919	22,151	22,434	22,738	22,858
40-49	26,003	28,372	30,893	33,222	34,996	37,105	38,784	40,318	41,522	42,687	43,744	45,016
50-59	32,509	35,766	38,180	41,320	44,763	48,715	52,814	56,611	60,334	63,382	66,546	70,147
60-64	20,957	22,507	23,959	25,366	26,906	28,692	30,106	31,532	32,967	34,910	36,818	38,496
65-69	24,774	26,588	27,856	29,559	30,816	32,066	33,394	34,536	35,780	36,822	37,937	38,962
70-79	39,091	43,769	47,367	51,757	56,154	59,671	62,839	65,549	67,213	69,530	70,917	71,917
80+	12,653	14,426	16,121	18,112	20,246	22,446	24,733	27,569	29,920	32,664	35,099	37,149
Unknown	.	*	*	*	*
0-19	1,957	1,970	2,001	2,039	2,040	2,096	2,060	2,131	2,185	2,281	2,259	2,365
20-44	37,713	39,899	41,516	43,227	44,761	46,245	47,587	48,548	49,242	49,631	50,210	50,991
45-64	67,238	73,653	79,080	85,019	90,930	97,959	104,581	110,905	116,817	122,767	128,579	134,577
65-74	47,927	52,293	55,216	58,862	62,134	64,791	67,291	69,539	71,528	73,486	75,185	76,680
75+	28,591	32,490	36,128	40,566	45,082	49,392	53,675	58,115	61,385	65,530	68,768	71,348
Unknown	.	*	*	*	*
Male	95,117	103,887	110,824	119,477	128,014	136,736	145,249	153,309	160,377	168,116	174,681	181,694
Female	88,309	96,420	103,114	110,233	116,930	123,746	129,941	135,925	140,776	145,577	150,316	154,236
Unknown	.	.	*	*	*	*	*	*	*	*	*	33
White	105,973	115,108	121,494	129,674	137,655	145,329	153,598	161,619	168,201	174,651	180,388	186,528
Black	68,883	75,321	80,834	86,746	92,571	98,889	103,897	108,423	112,390	116,972	121,067	124,098
Native American	2,482	2,729	2,997	3,247	3,466	3,792	4,055	4,282	4,503	4,647	4,753	4,910
Asian	5,695	6,571	7,378	8,118	8,832	9,660	10,543	11,384	12,169	13,050	13,734	14,328
Other/unknown	393	578	1,238	1,928	2,423	2,813	3,101	3,530	3,894	4,376	5,060	6,099
†Hispanic				24,548	27,545	30,239	33,381	37,408	39,943	42,751	45,717	48,610
†Non-Hispanic				205,165	217,402	230,244	241,813	251,830	261,214	270,945	279,285	287,353
Diabetes	59,489	67,363	75,223	84,065	92,972	101,298	108,815	116,837	123,654	130,363	136,494	141,988
Hypertension	57,220	62,534	64,544	67,569	70,744	74,299	78,045	81,366	84,420	87,990	91,809	94,482
Glomerulonephritis	29,338	31,266	32,704	34,303	35,585	36,784	37,744	38,252	38,735	39,136	39,149	39,373
Cystic kidney	7,032	7,407	7,600	7,749	7,827	8,086	8,355	8,574	8,660	8,748	8,782	8,918
Other urologic	4,945	5,165	5,783	6,335	6,826	7,235	7,866	8,214	8,443	8,766	8,868	8,960
Other cause	17,668	18,758	19,960	20,960	21,851	23,138	24,154	25,165	25,883	26,785	27,406	28,493
Unknown cause	6,971	7,339	7,711	8,351	8,806	9,340	9,914	10,545	11,078	11,518	11,915	12,153
Missing cause	763	475	416	381	336	303	301	285	284	390	579	1,596
All	183,426	200,307	213,941	229,713	244,947	260,483	275,194	289,238	301,157	313,696	325,002	335,963

The point prevalent cohorts are determined on December 31 of each calendar year without applying the 60-day stable modality rule.

The age of the point prevalent patient is determined as of December 31 of each calendar year.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

*Values for cells with ten or fewer patients are suppressed.

.. Zero values in this cell.

Table D.7

Counts of point prevalent ESRD patients, by mode of therapy: hemodialysis*December 31 point prevalent patients, by age, gender, race, ethnicity, & primary diagnosis*

	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992
0-4	25	22	23	32	34	43	46	46	43	47	43	44	30
5-9	83	69	74	66	57	39	50	57	59	52	57	57	59
10-14	225	233	228	223	179	164	138	152	159	150	169	159	175
15-19	791	788	762	684	648	614	587	605	653	688	660	654	685
20-29	3,790	3,963	4,174	4,309	4,382	4,429	4,417	4,485	4,737	5,110	5,313	5,439	5,742
30-39	5,905	6,487	7,000	7,481	7,942	8,285	8,727	9,182	9,813	10,725	11,283	12,088	12,982
40-49	7,266	7,827	8,283	9,280	9,814	10,070	10,532	11,345	12,546	14,124	15,602	17,292	18,973
50-59	10,955	12,083	13,170	14,035	14,632	15,164	15,732	16,360	17,665	19,037	20,542	22,510	24,762
60-64	5,741	6,672	7,501	8,651	9,496	10,142	10,592	11,508	12,305	13,353	14,455	15,640	16,630
65-69	5,170	5,767	6,408	7,837	8,660	9,442	10,618	12,058	13,328	14,902	16,443	18,007	19,849
70-79	5,513	6,465	7,514	9,719	11,214	12,543	14,373	16,229	18,279	21,108	24,002	27,862	31,479
80+	789	989	1,247	1,846	2,203	2,731	3,365	4,136	4,899	5,903	7,184	8,496	10,138
Unknown	*	*	*	11	15	16	12	*	*	*	*	*	.
0-19	1,124	1,112	1,087	1,005	918	860	821	860	914	937	929	914	949
20-44	13,086	14,019	14,995	16,143	16,856	17,384	18,139	18,971	20,501	22,562	24,242	25,830	27,742
45-64	20,571	23,013	25,133	27,613	29,410	30,706	31,861	33,909	36,565	39,787	42,953	47,139	51,347
65-74	8,816	9,960	11,251	13,928	15,530	17,021	19,218	21,622	23,964	27,125	30,495	34,331	38,273
75+	2,656	3,261	3,918	5,474	6,547	7,695	9,138	10,801	12,542	14,788	17,134	20,034	23,193
Unknown	*	*	*	11	15	16	12	*	*	*	*	*	.
Male	25,248	27,697	30,273	34,108	36,819	38,789	41,348	44,592	48,705	54,187	59,741	66,171	72,965
Female	21,008	23,672	26,117	30,065	32,457	34,893	37,841	41,577	45,787	51,018	56,018	62,081	68,539
Unknown	.	.	.	*
White	30,741	33,527	36,338	40,598	43,027	44,990	47,819	51,347	55,430	61,074	66,462	72,933	79,595
Black	14,282	16,380	18,448	21,734	24,206	26,331	28,694	31,789	35,482	40,102	44,654	49,903	55,670
Native American	261	354	428	561	628	729	837	958	1,133	1,298	1,449	1,637	1,884
Asian	309	421	610	810	1,006	1,286	1,521	1,798	2,177	2,544	3,004	3,566	4,089
Other/unknown	663	687	566	471	409	346	318	277	270	187	190	213	266
†Hispanic													
†Non-Hispanic													
Diabetes	4,297	5,918	7,762	9,783	12,027	14,152	16,652	19,546	22,981	27,720	32,755	38,475	44,607
Hypertension	7,994	10,142	12,635	15,316	17,609	19,640	22,021	24,827	28,042	32,225	36,004	40,469	45,509
Glomerulonephritis	9,382	10,521	11,730	13,159	14,082	14,852	15,671	16,573	17,493	18,783	19,835	20,947	22,057
Cystic kidney	3,029	3,352	3,726	4,160	4,367	4,531	4,597	4,751	4,876	4,995	5,066	5,272	5,379
Other urologic	1,140	1,413	1,740	2,107	2,411	2,716	2,914	3,226	3,486	3,687	3,763	4,036	4,221
Other cause	4,586	5,258	6,195	7,136	7,803	8,359	8,897	9,317	10,079	11,057	11,841	12,545	13,416
Unknown cause	4,903	5,099	4,922	5,148	5,240	5,083	5,162	5,409	5,476	5,239	5,268	5,528	5,664
Missing cause	10,925	9,666	7,680	7,365	5,737	4,349	3,275	2,520	2,059	1,499	1,227	980	651
All	46,256	51,369	56,390	64,174	69,276	73,682	79,189	86,169	94,492	105,205	115,759	128,252	141,504

The point prevalent cohorts are determined on December 31 of each calendar year without applying the 60-day stable modality rule. The age of the point prevalent patient is determined as of December 31 of each calendar year.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

*Values for cells with ten or fewer patients are suppressed.

“.” Zero values in this cell.

Table D.7 (continued)

Counts of point prevalent ESRD patients, by mode of therapy: hemodialysis

December 31 point prevalent patients, by age, gender, race, ethnicity, & primary diagnosis

	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004
0-4	46	50	57	50	46	46	48	58	55	49	46	67
5-9	64	68	69	78	84	88	85	105	96	92	74	94
10-14	176	203	200	190	183	212	211	242	265	289	268	255
15-19	703	674	730	744	775	817	828	795	827	894	919	938
20-29	5,904	6,193	6,381	6,691	6,929	7,290	7,465	7,593	7,639	7,629	7,613	7,748
30-39	13,721	14,588	15,287	16,020	16,824	17,445	18,173	18,781	19,072	19,408	19,777	20,002
40-49	20,767	22,669	24,918	27,459	29,457	31,929	33,771	35,420	36,807	38,058	39,100	40,376
50-59	27,074	29,681	31,916	34,996	38,614	42,779	46,815	50,719	54,412	57,408	60,446	64,011
60-64	17,894	19,201	20,522	22,105	23,824	25,858	27,372	28,860	30,361	32,203	33,951	35,627
65-69	21,300	22,917	24,146	25,934	27,590	29,169	30,552	31,770	33,117	34,168	35,299	36,326
70-79	34,594	38,841	42,363	46,673	51,386	55,254	58,508	61,406	63,346	65,563	66,906	67,938
80+	11,673	13,302	14,943	16,861	19,041	21,379	23,551	26,424	28,799	31,465	33,839	35,886
Unknown	.	*	*
0-19	989	995	1,056	1,062	1,088	1,163	1,172	1,200	1,243	1,324	1,307	1,354
20-44	29,315	31,057	32,798	34,926	36,883	38,941	40,438	41,710	42,561	43,233	43,853	44,740
45-64	56,045	61,275	66,226	72,345	78,765	86,360	93,158	99,663	105,730	111,473	117,034	123,024
65-74	41,559	45,483	48,394	52,130	56,062	59,228	61,859	64,357	66,634	68,560	70,180	71,744
75+	26,008	29,577	33,058	37,338	41,955	46,574	50,752	55,243	58,628	62,636	65,864	68,406
Unknown	.	*	*
Male	79,631	87,181	93,965	103,056	112,585	122,346	131,062	139,431	146,962	154,523	160,953	167,876
Female	74,285	81,207	87,565	94,743	102,166	109,919	116,314	122,740	127,832	132,701	137,280	141,362
Unknown	.	.	*	*	*	*	*	*	*	*	*	31
White	85,505	93,206	99,421	108,010	117,270	126,480	135,001	143,634	150,795	157,238	162,835	169,127
Black	61,150	66,866	72,338	78,471	84,740	91,473	96,656	101,389	105,513	110,089	114,104	117,151
Native American	2,128	2,342	2,599	2,870	3,088	3,438	3,735	3,930	4,147	4,288	4,396	4,581
Asian	4,816	5,499	6,133	6,824	7,568	8,387	9,235	10,041	10,815	11,631	12,256	12,835
Other/unknown	317	475	1,041	1,626	2,087	2,488	2,752	3,179	3,526	3,980	4,647	5,575
†Hispanic				21,425	24,405	27,176	30,156	34,093	36,681	39,307	42,220	45,154
†Non-Hispanic				176,376	190,348	205,090	217,223	228,080	238,115	247,919	256,018	264,115
Diabetes	50,430	57,233	64,607	73,300	82,715	91,735	99,336	107,571	114,633	121,252	127,251	132,954
Hypertension	49,709	54,368	56,599	60,079	63,836	67,930	71,667	75,132	78,529	81,913	85,591	88,218
Glomerulonephritis	23,288	24,778	26,021	27,686	29,235	30,830	32,087	32,776	33,452	33,937	34,006	34,218
Cystic kidney	5,568	5,873	6,049	6,224	6,433	6,808	7,098	7,347	7,440	7,596	7,554	7,705
Other urologic	4,194	4,375	4,937	5,476	5,984	6,421	7,028	7,380	7,620	7,917	8,021	8,115
Other cause	14,189	15,173	16,380	17,510	18,598	20,036	21,066	22,245	22,852	23,769	24,396	25,480
Unknown cause	5,929	6,220	6,607	7,227	7,694	8,271	8,868	9,527	10,063	10,542	10,939	11,172
Missing cause	609	368	332	299	258	235	229	195	207	300	480	1,407
All	153,916	168,388	181,532	197,801	214,753	232,266	247,379	262,173	274,796	287,226	298,238	309,269

The point prevalent cohorts are determined on December 31 of each calendar year without applying the 60-day stable modality rule.

The age of the point prevalent patient is determined as of December 31 of each calendar year.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

*Values for cells with ten or fewer patients are suppressed.

.. " Zero values in this cell.

Table D.8

Counts of point prevalent ESRD patients, by mode of therapy: peritoneal dialysis*December 31 point prevalent patients, by age, gender, race, ethnicity, & primary diagnosis*

	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992
0-4	11	32	54	69	78	105	118	101	102	104	110	140	148
5-9	*	20	45	72	87	72	92	90	88	114	116	105	99
10-14	17	33	67	120	145	139	159	167	171	163	192	213	208
15-19	11	39	91	126	158	230	216	238	242	290	300	330	350
20-29	65	194	301	529	682	770	842	926	1,042	1,090	1,262	1,376	1,489
30-39	146	378	621	1,007	1,326	1,644	1,721	1,878	2,090	2,336	2,735	3,075	3,382
40-49	138	388	663	1,160	1,435	1,763	1,932	2,078	2,355	2,749	3,243	3,891	4,344
50-59	228	652	956	1,487	1,942	2,267	2,469	2,620	2,721	3,091	3,559	4,007	4,574
60-64	78	338	546	864	1,132	1,436	1,565	1,733	1,826	1,983	2,256	2,359	2,707
65-69	88	252	433	606	888	1,197	1,439	1,570	1,712	1,925	2,190	2,606	2,888
70-79	91	246	518	637	927	1,281	1,492	1,722	1,880	2,136	2,512	3,124	3,631
80+	13	49	94	111	154	207	255	310	354	432	515	626	726
Unknown	.	.	.	*	*	*	*	*
0-19	48	124	257	387	468	546	585	596	603	671	718	788	805
20-44	275	761	1,230	2,079	2,692	3,240	3,531	3,853	4,304	4,765	5,617	6,400	7,005
45-64	380	1,189	1,857	2,968	3,825	4,640	4,998	5,382	5,730	6,484	7,438	8,308	9,491
65-74	147	416	786	1,017	1,503	2,046	2,396	2,647	2,930	3,272	3,774	4,575	5,178
75+	45	131	259	337	466	639	790	955	1,016	1,221	1,443	1,781	2,067
Unknown	.	.	.	*	*	*	*	*
Male	468	1,351	2,298	3,701	4,795	5,925	6,454	7,059	7,638	8,635	9,948	11,566	12,879
Female	427	1,270	2,091	3,088	4,161	5,188	5,847	6,376	6,945	7,778	9,042	10,286	11,667
Unknown
White	732	2,065	3,378	5,247	6,810	8,474	9,256	10,025	10,819	11,939	13,679	15,568	17,362
Black	138	503	919	1,376	1,898	2,361	2,710	3,000	3,332	3,947	4,696	5,536	6,214
Native American	13	20	38	66	114	119	152	184	181	197	233	267	329
Asian	*	20	43	68	111	134	157	205	228	311	363	457	610
Other/unknown	*	13	11	32	23	25	26	21	23	19	19	24	31
†Hispanic													
†Non-Hispanic													
Diabetes	203	547	1,019	1,421	2,012	2,530	2,923	3,326	3,742	4,483	5,382	6,474	7,653
Hypertension	171	498	933	1,302	1,731	2,241	2,647	2,919	3,269	3,790	4,636	5,474	6,159
Glomerulonephritis	222	607	953	1,626	2,201	2,714	2,933	3,218	3,515	3,830	4,236	4,715	5,127
Cystic kidney	64	179	302	456	585	721	806	832	831	881	1,009	1,130	1,249
Other urologic	25	88	144	203	283	358	378	392	425	481	528	560	622
Other cause	107	303	546	892	1,171	1,484	1,576	1,712	1,831	2,066	2,314	2,604	2,843
Unknown cause	77	223	322	459	551	608	658	686	671	672	723	765	804
Missing cause	26	176	170	430	422	457	380	350	299	210	162	130	89
All	895	2,621	4,389	6,789	8,956	11,113	12,301	13,435	14,583	16,413	18,990	21,852	24,546

The point prevalent cohorts are determined on December 31 of each calendar year without applying the 60-day stable modality rule.

The age of the point prevalent patient is determined as of December 31 of each calendar year.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

*Values for cells with ten or fewer patients are suppressed.

“.” Zero values in this cell.

Table D.8 (continued)

Counts of point prevalent ESRD patients, by mode of therapy: peritoneal dialysis

December 31 point prevalent patients, by age, gender, race, ethnicity, & primary diagnosis

	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004
0-4	144	154	163	171	152	166	160	179	164	174	188	213
5-9	105	137	135	132	134	113	118	132	135	138	137	139
10-14	210	214	209	216	232	227	207	234	238	266	244	262
15-19	363	356	345	373	357	336	329	317	318	308	320	343
20-29	1,624	1,673	1,660	1,617	1,579	1,479	1,365	1,344	1,334	1,248	1,245	1,221
30-39	3,699	3,900	3,843	3,671	3,390	3,153	3,101	2,931	2,893	2,848	2,796	2,714
40-49	4,803	5,225	5,588	5,485	5,273	4,914	4,742	4,622	4,478	4,408	4,452	4,456
50-59	5,025	5,635	5,966	6,050	5,923	5,687	5,692	5,627	5,736	5,758	5,900	5,921
60-64	2,812	3,040	3,246	3,132	2,985	2,743	2,616	2,573	2,527	2,614	2,778	2,779
65-69	3,218	3,379	3,465	3,337	3,053	2,764	2,675	2,600	2,606	2,598	2,569	2,568
70-79	4,115	4,512	4,631	4,539	4,382	4,141	3,921	3,777	3,783	3,860	3,902	3,912
80+	844	983	1,043	1,036	1,048	970	988	984	1,078	1,138	1,206	1,236
Unknown	*	*	*
0-19	822	861	852	892	875	842	814	862	855	886	889	957
20-44	7,641	8,039	8,127	7,830	7,440	6,849	6,647	6,365	6,255	6,015	6,027	5,936
45-64	10,322	11,434	12,176	12,125	11,710	11,127	10,869	10,732	10,713	10,861	11,144	11,155
65-74	5,872	6,278	6,358	6,141	5,687	5,286	5,046	4,822	4,793	4,817	4,872	4,824
75+	2,305	2,596	2,781	2,771	2,796	2,589	2,538	2,539	2,674	2,779	2,805	2,892
Unknown	*	*	*
Male	14,134	15,223	15,714	15,286	14,559	13,579	13,158	12,947	12,831	12,990	13,158	13,295
Female	12,828	13,985	14,580	14,473	13,949	13,114	12,756	12,373	12,459	12,369	12,580	12,469
Unknown	*
White	18,729	20,017	20,606	20,074	19,166	17,770	17,226	16,727	16,711	16,691	16,851	16,808
Black	7,055	7,745	7,954	7,818	7,455	7,066	6,845	6,665	6,583	6,592	6,713	6,705
Native American	338	375	390	368	369	345	309	337	345	353	349	322
Asian	803	1,010	1,189	1,242	1,222	1,218	1,227	1,281	1,317	1,365	1,442	1,455
Other/unknown	37	61	155	257	296	294	307	310	334	358	383	475
†Hispanic				2,962	2,991	2,914	3,040	3,167	3,133	3,298	3,362	3,309
†Non-Hispanic				26,797	25,517	23,779	22,874	22,153	22,157	22,061	22,376	22,456
Diabetes	8,353	9,344	10,007	10,124	9,792	9,164	8,914	8,767	8,814	8,870	8,974	8,803
Hypertension	6,891	7,508	7,462	6,963	6,525	6,049	5,957	5,832	5,687	5,836	6,022	6,120
Glomerulonephritis	5,579	5,984	6,261	6,232	5,987	5,591	5,261	5,126	4,993	4,911	4,917	4,922
Cystic kidney	1,357	1,421	1,469	1,443	1,334	1,231	1,201	1,150	1,176	1,107	1,172	1,159
Other urologic	684	710	768	769	771	749	752	757	772	796	796	799
Other cause	3,140	3,238	3,315	3,194	3,058	2,899	2,866	2,739	2,867	2,885	2,879	2,895
Unknown cause	885	955	975	1,005	1,015	985	935	925	963	928	929	951
Missing cause	73	48	37	29	26	25	28	24	18	26	49	116
All	26,962	29,208	30,294	29,759	28,508	26,693	25,914	25,320	25,290	25,359	25,738	25,765

The point prevalent cohorts are determined on December 31 of each calendar year without applying the 60-day stable modality rule.

The age of the point prevalent patient is determined as of December 31 of each calendar year.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

*Values for cells with ten or fewer patients are suppressed.

“. . .” Zero values in this cell.

Table D.9

Counts of point prevalent ESRD patients, by mode of therapy: functioning transplant*December 31 point prevalent patients, by age, gender, race, ethnicity, & primary diagnosis*

	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992
0-4	30	46	75	89	100	126	135	173	177	174	163	174	191
5-9	113	129	156	172	221	290	341	377	406	466	506	563	565
10-14	305	337	383	428	489	533	562	613	663	724	776	814	880
15-19	704	794	845	937	1,008	1,100	1,224	1,321	1,341	1,345	1,366	1,388	1,404
20-29	2,676	3,232	3,771	4,272	4,755	5,289	5,886	6,241	6,472	6,640	6,977	7,231	7,327
30-39	2,851	3,755	4,640	5,679	6,907	8,254	9,661	10,762	11,793	12,748	13,813	14,818	15,668
40-49	1,972	2,482	3,139	3,874	4,730	5,887	7,269	8,741	10,190	11,636	13,026	14,791	16,481
50-59	1,194	1,541	1,967	2,446	3,124	3,845	4,917	5,948	6,934	7,927	9,053	10,126	11,508
60-64	171	235	315	425	599	834	1,174	1,579	2,071	2,529	3,002	3,509	3,964
65-69	59	73	95	122	169	258	379	588	825	1,085	1,394	1,758	2,204
70-79	16	23	27	37	52	78	114	178	245	328	469	676	902
80+	*	*	*	*	*	12	17	16	17	18	26	33	33
Unknown	*	*	*	*	*	*	*	*	*	*	*	*	*
0-19	1,152	1,306	1,459	1,626	1,818	2,049	2,262	2,484	2,587	2,709	2,811	2,939	3,040
20-44	6,593	8,352	10,150	12,078	14,259	16,737	19,547	21,768	23,774	25,736	27,999	30,145	31,851
45-64	2,271	2,893	3,682	4,618	5,856	7,372	9,360	11,503	13,686	15,744	17,872	20,330	23,097
65-74	72	88	115	152	213	322	472	728	1,018	1,344	1,772	2,318	2,969
75+	*	*	11	*	13	26	38	54	69	87	117	149	170
Unknown	*	*	*	*	*	*	*	*	*	*	*	*	*
Male	6,032	7,657	9,401	11,289	13,553	16,264	19,427	22,365	25,018	27,620	30,491	33,535	36,591
Female	4,065	4,994	6,019	7,197	8,607	10,243	12,253	14,172	16,115	17,999	20,079	22,345	24,535
Unknown	.	*	.	.	*	*	*	*	*	*	*	*	*
White	8,187	10,279	12,489	14,899	17,818	21,202	25,275	29,102	32,632	36,259	40,154	44,335	48,380
Black	1,542	1,937	2,413	2,947	3,544	4,352	5,234	6,009	6,758	7,366	8,111	8,959	9,830
Native American	69	93	117	141	180	220	255	299	361	428	478	544	594
Asian	95	128	186	258	360	451	608	777	978	1,153	1,384	1,586	1,860
Other/unknown	204	215	215	241	260	284	310	352	406	415	445	458	464
†Hispanic													
†Non-Hispanic													
Diabetes	855	1,238	1,720	2,289	2,956	3,877	5,019	6,037	7,024	8,128	9,296	10,587	11,740
Hypertension	1,042	1,354	1,737	2,225	2,712	3,380	4,114	4,836	5,550	6,203	7,018	7,767	8,673
Glomerulonephritis	3,453	4,318	5,283	6,285	7,566	8,939	10,474	11,955	13,354	14,650	16,124	17,711	19,212
Cystic kidney	435	587	756	950	1,231	1,538	1,978	2,464	2,932	3,369	3,859	4,344	4,907
Other urologic	437	568	679	837	997	1,186	1,393	1,580	1,743	1,926	2,109	2,337	2,530
Other cause	1,620	2,031	2,459	2,965	3,570	4,228	5,049	5,702	6,180	6,724	7,306	8,041	8,729
Unknown cause	823	1,014	1,177	1,316	1,476	1,668	1,872	2,091	2,294	2,485	2,635	2,796	2,961
Missing cause	1,432	1,542	1,609	1,619	1,654	1,693	1,783	1,874	2,058	2,136	2,225	2,299	2,376
All	10,097	12,652	15,420	18,486	22,162	26,509	31,682	36,539	41,135	45,621	50,572	55,882	61,128

The point prevalent cohorts are determined on December 31 of each calendar year without applying the 60-day stable modality rule.

The age of the point prevalent patient is determined as of December 31 of each calendar year.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

*Values for cells with ten or fewer patients are suppressed.

“.” Zero values in this cell.

Table D.9 (continued)

Counts of point prevalent ESRD patients, by mode of therapy: functioning transplant

December 31 point prevalent patients, by age, gender, race, ethnicity, & primary diagnosis

	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004
0-4	200	198	186	212	209	213	235	247	265	267	257	279
5-9	592	584	609	625	688	677	697	657	697	709	759	775
10-14	932	1,013	1,095	1,164	1,158	1,232	1,287	1,309	1,309	1,361	1,374	1,362
15-19	1,479	1,648	1,775	1,809	1,903	1,938	2,080	2,173	2,208	2,235	2,374	2,491
20-29	7,413	7,394	7,480	7,627	7,715	7,763	7,781	7,776	7,795	7,864	7,963	8,190
30-39	16,511	17,302	18,034	18,612	18,920	19,421	19,606	19,912	20,084	20,186	20,051	20,013
40-49	18,270	20,016	21,869	23,446	24,777	26,273	27,646	29,157	30,378	31,477	32,535	33,659
50-59	12,945	14,386	15,841	17,601	19,874	22,158	24,417	26,671	29,187	31,625	33,969	36,757
60-64	4,410	4,900	5,510	6,236	6,913	7,717	8,533	9,319	10,270	11,471	12,728	13,943
65-69	2,712	3,175	3,659	4,204	4,718	5,255	5,891	6,547	7,306	8,114	9,036	9,950
70-79	1,133	1,447	1,795	2,188	2,700	3,253	3,786	4,517	5,226	6,177	7,092	8,123
80+	38	50	59	86	97	130	179	231	295	377	466	594
Unknown	*	*	*	*	*	*	*	*	*	*	*	.
0-19	3,203	3,443	3,665	3,810	3,958	4,060	4,299	4,386	4,479	4,572	4,764	4,907
20-44	33,576	35,013	36,623	37,913	38,924	40,140	41,020	41,780	42,423	42,985	43,283	43,843
45-64	25,973	28,985	32,111	35,609	39,275	43,192	46,963	51,055	55,291	59,638	63,963	68,719
65-74	3,667	4,388	5,121	5,964	6,860	7,797	8,804	10,007	11,273	12,730	14,254	15,886
75+	216	284	392	514	655	841	1,052	1,288	1,554	1,938	2,340	2,781
Unknown	*	*	*	*	*	*	*	*	*	*	.	.
Male	39,794	43,013	46,501	49,915	53,419	57,038	60,623	64,379	68,190	72,239	76,227	80,594
Female	26,841	29,099	31,409	33,893	36,250	38,989	41,512	44,133	46,826	49,620	52,371	55,537
Unknown	*	*	*	*	*	*	*	*	*	*	*	*
White	52,659	56,545	60,701	64,963	69,219	73,923	78,381	83,037	87,702	92,715	97,333	102,185
Black	10,748	11,952	13,237	14,503	15,711	16,914	18,083	19,290	20,604	21,943	23,382	24,965
Native American	650	729	792	846	906	966	1,061	1,129	1,189	1,248	1,298	1,372
Asian	2,103	2,410	2,697	3,002	3,315	3,674	4,018	4,400	4,797	5,178	5,656	6,176
Other/unknown	477	478	487	498	522	554	596	661	729	780	935	1,438
†Hispanic				7,367	8,113	9,097	10,022	11,026	12,124	13,372	14,595	15,905
†Non-Hispanic				76,445	81,560	86,934	92,117	97,491	102,897	108,492	114,009	120,231
Diabetes	13,284	14,708	16,213	17,835	19,326	20,958	22,472	24,059	25,718	27,529	29,161	30,950
Hypertension	9,534	10,524	11,510	12,478	13,343	14,234	15,009	15,852	16,852	17,868	18,785	19,999
Glomerulonephritis	20,617	22,018	23,506	24,969	26,460	28,106	29,704	31,304	32,778	34,415	35,999	37,748
Cystic kidney	5,395	5,864	6,446	6,994	7,642	8,297	8,893	9,524	10,215	10,938	11,767	12,479
Other urologic	2,771	2,954	3,189	3,415	3,631	3,867	4,080	4,307	4,561	4,832	5,094	5,338
Other cause	9,518	10,281	11,069	11,878	12,670	13,533	14,396	15,302	16,190	17,097	17,991	19,091
Unknown cause	3,119	3,285	3,414	3,599	3,867	4,122	4,440	4,758	5,157	5,544	5,964	6,315
Missing cause	2,399	2,480	2,567	2,644	2,734	2,914	3,145	3,411	3,550	3,641	3,843	4,216
All	66,637	72,114	77,914	83,812	89,673	96,031	102,139	108,517	115,021	121,864	128,604	136,136

The point prevalent cohorts are determined on December 31 of each calendar year without applying the 60-day stable modality rule.

The age of the point prevalent patient is determined as of December 31 of each calendar year.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

*Values for cells with ten or fewer patients are suppressed.

.. Zero values in this cell.

Table D.10

Incident ESRD patients, 2004

by age, gender, race/ethnicity, primary diagnosis, & modality

	Center hemo	Center self hemo	Home hemo	CAPD	CCPD	Other PD	Uncertain dialysis	Transplant	All
0-4	50	.	.	15	134	*	*	41	248
5-9	58	.	.	*	54	.	*	31	153
10-14	147	.	*	*	116	*	*	44	321
15-19	431	.	.	35	78	*	*	93	644
20-29	2,177	.	*	175	80	*	*	183	2,626
30-39	4,853	*	14	376	192	*	19	313	5,776
40-49	10,328	*	28	671	316	13	32	513	11,904
50-59	17,530	*	52	1,040	472	25	43	608	19,772
60-64	10,593	*	35	509	229	21	16	208	11,612
65-69	11,207	*	30	554	144	47	39	143	12,168
70-79	23,390	*	45	790	274	93	61	81	24,742
80+	13,839	*	48	295	120	59	27	*	14,395
Unknown	*	*
0-19	686	.	*	67	382	*	*	209	1,366
20-44	11,259	*	28	859	424	15	33	726	13,347
45-64	34,222	*	107	1,912	865	53	80	1,099	38,343
65-74	22,875	*	52	1,013	300	98	75	212	24,634
75+	25,561	*	71	626	238	101	52	14	26,671
Unknown	*	*
Male	52,182	17	158	2,401	1,245	146	130	1,274	57,553
Female	42,393	*	102	2,076	963	131	118	986	46,777
Unknown	31	.	.	.	*	.	*	.	34
White	60,690	16	169	3,170	1,577	219	182	1,764	67,787
Black	27,302	*	74	938	450	37	38	187	29,033
Native American	1,092	.	*	53	11	*	*	*	1,171
Asian	3,347	*	*	220	67	*	11	50	3,714
Other/unknown	2,175	.	*	96	104	*	16	251	2,659
Hispanic	12,536	.	30	430	335	43	22	137	13,533
Non-Hispanic	82,070	25	230	4,047	1,874	234	228	2,123	90,831
Diabetes	42,484	*	97	1,907	767	110	82	415	45,871
Hypertension	26,254	*	87	1,063	414	80	35	192	28,132
Glomerulonephritis	7,005	*	12	636	401	16	20	396	8,490
Cystic kidney	1,644	*	*	222	110	*	*	294	2,295
Other urologic	2,492	.	*	119	69	11	12	129	2,837
Other cause	9,628	*	22	344	331	32	31	313	10,705
Unknown cause	3,698	.	22	132	91	*	*	96	4,055
Missing cause	1,401	.	*	54	26	15	50	425	1,979
All	94,606	25	260	4,477	2,209	277	250	2,260	104,364

The incident cohorts are determined at the time of ESRD initiation without applying the 60-day stable modality rule.

The age of the incident patient is determined as of the date of ESRD initiation.

*Values for cells with ten or fewer patients are suppressed.

“ . ” Zero values in this cell.

on our website & CD
Incident ESRD patients, 1995 & 1999: by age, gender, race/ethnicity, primary diagnosis, & modality (Table D.10.1).

Table D.11

Point prevalent ESRD patients, 2004

December 31 point prevalent patients, by age, gender, race, ethnicity, primary diagnosis, & modality

	Center hemo	Center self hemo	Home hemo	CAPD	CCPD	Other PD	Uncertain dialysis	Transplant	All
0-4	64	.	*	16	197	*	*	279	566
5-9	89	.	*	15	124	.	*	775	1,012
10-14	248	.	*	22	240	*	13	1,362	1,893
15-19	926	*	11	50	293	*	27	2,491	3,801
20-29	7,697	*	42	453	768	*	81	8,190	17,241
30-39	19,823	20	159	1,197	1,517	*	139	20,013	42,871
40-49	40,009	42	325	1,963	2,493	*	180	33,659	78,675
50-59	63,524	40	447	2,646	3,275	11	204	36,757	106,904
60-64	35,401	24	202	1,328	1,451	*	82	13,943	52,439
65-69	36,115	18	193	1,088	1,480	13	55	9,950	48,912
70-79	67,581	20	337	1,614	2,298	*	58	8,123	80,040
80+	35,644	19	223	466	770	*	21	594	37,743
Unknown	*	.	.	.	*	.	.	.	*
0-19	1,327	*	26	103	854	*	49	4,907	7,272
20-44	44,355	49	336	2,526	3,410	*	309	43,843	94,834
45-64	122,099	86	839	5,061	6,094	21	377	68,719	203,296
65-74	71,347	29	368	2,028	2,796	19	93	15,886	92,566
75+	67,993	28	385	1,140	1,752	*	41	2,781	74,129
Unknown	*	.	.	.	*	.	.	.	*
Male	166,624	109	1,143	5,410	7,885	30	493	80,594	262,288
Female	140,468	84	810	5,448	7,021	30	375	55,537	209,773
Unknown	30	.	*	.	*	.	*	*	38
White	167,744	103	1,280	6,930	9,878	37	556	102,185	288,713
Black	116,488	80	583	2,839	3,866	*	233	24,965	149,063
Native American	4,570	*	*	175	147	*	*	1,372	6,282
Asian	12,769	*	60	723	732	*	37	6,176	20,504
Other/unknown	5,551	*	21	191	284	12	37	1,438	7,537
Hispanic	44,986	19	149	1,286	2,023	22	125	15,905	64,515
Non-Hispanic	262,136	174	1,805	9,572	12,884	38	744	120,231	407,584
Diabetes	132,271	56	627	3,893	4,910	21	210	30,950	172,938
Hypertension	87,671	58	489	2,728	3,392	14	130	19,999	114,481
Glomerulonephritis	33,809	36	373	1,990	2,932	*	231	37,748	77,121
Cystic kidney	7,609	*	87	498	661	*	53	12,479	21,397
Other urologic	8,039	*	70	294	505	*	44	5,338	14,298
Other cause	25,255	21	204	1,013	1,882	*	108	19,091	47,584
Unknown cause	11,075	*	91	380	571	*	27	6,315	18,468
Missing cause	1,393	*	13	62	54	*	66	4,216	5,812
All	307,122	193	1,954	10,858	14,907	60	869	136,136	472,099

The point prevalent cohorts are determined on December 31 of each calendar year without applying the 60-day stable modality rule.

The age of the point prevalent patient is determined as of December 31 of each calendar year.

*Values for cells with ten or fewer patients are suppressed.

“.” Zero values in this cell.

on our website & CD

Prevalent ESRD patients, 1995 & 1999 (Table D.11.1). Counts of incident ESRD patients for selected years (Table D.a). Living ESRD patients on December 31 for selected years (D.b). Incident ESRD patients for selected years (D.c). Living ESRD patients on December 31 for selected years, by age & ESRD network of residence (D.d).

Table D.12

Treatment status two years after first ESRD service, 2000-2002

incident patients with Medicare coverage, 2000-2002 combined

ALL	% on Day 90	Count	Treatment status two years after first ESRD service (percent of patients)						
			Center hemo	Home hemo	CAPD & CCPD	Oth/unk dialysis	Transplant	Death	Lost to Followup
Age at first service									
0-19		1,464	29.0	0.5	17.1	0.8	45.8	5.5	1.4
20-44		19,387	59.4	0.4	8.9	0.1	14.2	15.2	1.9
45-64		51,109	61.1	0.4	5.7	.	5.3	26.2	1.4
65-74		50,026	52.5	0.2	4.3	.	2.1	39.1	1.7
75+		48,070	42.5	0.1	2.1	.	0.2	53.8	1.3
Modality on day 90									
Center hemodialysis		152,296	56.8	0.2	1.5	.	2.8	37.1	1.6
Home hemodialysis		668	21.6	9.3	8.8	.	3.0	55.8	1.5
CAPD/CCPD		13,722	18.1	1.1	40.6	0.1	8.4	31.3	0.5
Other/unknown dialysis		1,518	46.0	0.1	5.1	1.1	2.1	43.5	2.0
Transplant		1,852	1.8	.	0.2	0.2	93.7	4.1	0.1
Interaction of age at first service & modality on day 90									
0-19	Center hemodialysis	730	50.1	0.5	5.9	0.5	34.8	6.4	1.6
	Home hemodialysis	*	.	.	12.5	.	50.0	37.5	.
	CAPD/CCPD	523	10.1	0.8	39.4	1.0	41.9	5.2	1.7
	Other/unknown dialysis	*	28.6	.	.	14.3	28.6	28.6	.
	Transplant	196	1.5	.	.	0.5	97.4	0.5	.
20-44	Center hemodialysis	16,424	66.8	0.2	3.9	0.1	10.6	16.2	2.2
	Home hemodialysis	73	32.9	13.7	19.2	.	12.3	17.8	4.1
	CAPD/CCPD	2,244	21.3	1.0	47.9	.	18.7	10.7	0.4
	Other/unknown dialysis	41	41.5	.	4.9	4.9	14.6	26.8	7.3
	Transplant	605	2.1	.	0.3	0.2	94.9	2.3	0.2
45-64	Center hemodialysis	45,451	66.2	0.2	1.9	.	3.6	26.6	1.5
	Home hemodialysis	151	29.8	13.9	11.9	.	4.6	37.1	2.6
	CAPD/CCPD	4,556	20.5	1.4	44.2	.	8.1	25.4	0.4
	Other/unknown dialysis	233	47.6	0.4	4.7	2.1	4.3	36.9	3.9
	Transplant	718	1.7	.	.	0.1	93.3	4.9	.
65-74	Center hemodialysis	45,020	56.0	0.1	1.3	.	1.4	39.3	1.9
	Home hemodialysis	180	21.1	7.8	9.4	.	.	61.1	0.6
	CAPD/CCPD	3,902	17.1	1.0	39.1	0.1	3.4	38.7	0.6
	Other/unknown dialysis	615	49.8	.	6.5	0.8	2.0	38.9	2.1
	Transplant	309	1.6	.	0.3	.	90.6	7.4	.
75+	Center hemodialysis	44,671	44.3	0.1	0.5	.	0.1	53.7	1.4
	Home hemodialysis	256	14.5	6.6	3.5	.	.	74.6	0.8
	CAPD/CCPD	2,497	13.7	0.7	30.0	.	0.4	54.6	0.6
	Other/unknown dialysis	622	42.1	.	4.0	0.6	0.3	51.9	1.0
	Transplant	24	87.5	12.5	.
All		170,056	52.8	0.3	4.7	.	4.3	36.4	1.5

The incident cohorts are determined at the time of ESRD initiation without applying the 60-day stable modality rule.

The age of the incident patient is determined as of the date of ESRD initiation.

Includes only incident patients with known age & patients who have Medicare as their primary payor, are receiving their first ESRD service, & survive the first 90 days.

*Values for cells with ten or fewer patients are suppressed.

“.” Zero values in this cell.

on our website & CD

Treatment status two years after first ESRD service, 1999-2001 (Tables D.12.1-18).

Table D.13

Point prevalent ESRD patients, 2004: by patient vintage

December 31 point prevalent patients, by year-end treatment modality & number of years patient has had ESRD (vintage)

	Dialysis	Functioning graft	Center hemo	Center self hemo	Home hemo	CAPD	CCPD	Other PD	Uncertain dialysis	All
0	86,252	3,595	78,495	32	405	3,700	3,471	29	120	89,847
1	63,822	6,102	57,764	26	328	2,483	3,106	*	110	69,924
2	46,140	7,992	41,989	28	199	1,426	2,374	*	114	54,132
3	34,356	9,223	31,384	15	208	879	1,824	.	46	43,579
4	25,032	10,064	23,161	15	143	548	1,123	*	39	35,096
5	18,547	10,362	17,318	*	92	361	717	*	48	28,909
6	13,329	10,139	12,449	13	68	271	479	*	46	23,468
7	9,780	9,225	9,131	*	74	218	305	.	45	19,005
8	7,471	8,508	6,960	*	58	161	246	*	39	15,979
9	5,687	7,694	5,261	*	43	123	208	.	47	13,381
10	4,503	7,003	4,145	*	33	118	174	*	26	11,506
11	3,635	6,225	3,338	*	32	98	137	*	27	9,860
12	3,002	5,665	2,738	*	26	91	115	.	29	8,667
13	2,353	4,761	2,137	*	29	63	97	.	25	7,114
14	2,057	4,228	1,870	*	15	50	94	.	24	6,285
15	1,697	3,597	1,543	*	13	43	74	.	22	5,294
16	1,453	3,281	1,313	*	19	41	66	*	11	4,734
17	1,124	2,700	1,010	*	19	35	47	.	11	3,824
18	943	2,381	841	*	15	31	50	.	*	3,324
19	789	2,045	694	*	14	20	51	*	*	2,834
20	732	1,864	663	*	18	16	31	.	*	2,596
21	601	1,624	548	*	13	16	20	.	*	2,225
22	502	1,534	459	*	11	*	16	.	*	2,036
23	389	1,225	350	.	12	11	13	.	*	1,614
24	348	1,098	312	*	*	*	17	.	*	1,446
25	322	879	287	*	14	*	14	.	*	1,201
26	267	821	239	*	12	*	*	.	*	1,088
27	266	744	232	*	11	12	*	.	*	1,010
28	153	436	140	*	*	*	*	.	.	589
29	124	298	108	*	*	*	*	.	*	422
30	114	263	92	*	*	*	*	.	*	377
31	76	233	65	.	*	*	*	.	*	309
32	38	107	32	.	.	*	*	.	.	145
33	15	82	15	97
34	*	40	*	.	.	*	*	.	.	50
35	*	38	*	*	43
36	29	60	28	.	.	.	*	.	.	89
All	335,963	136,136	307,122	193	1,954	10,858	14,907	60	869	472,099

The point prevalent cohorts are determined on December 31 of each calendar year without applying the 60-day stable modality rule.
 *Values for cells with ten or fewer patients are suppressed.
 ". " Zero values in this cell.

Table D.14

Point prevalent ESRD patients, 2004: by number of years on modality*December 31 point prevalent patients, by year-end treatment modality*

	Dialysis	Functioning graft	Center hemo	Center self hemo	Home hemo	CAPD	CCPD	Other PD	Uncertain dialysis	All
0	220,090	15,906	201,736	152	1,595	6,462	9,405	40	700	235,996
1	60,256	14,290	54,032	19	214	2,589	3,313	*	84	74,546
2	27,358	13,269	24,797	12	77	1,056	1,348	*	59	40,627
3	11,977	12,142	11,149	*	27	332	458	*	*	24,119
4	6,641	10,726	6,256	*	11	162	207	.	*	17,367
5	3,767	9,570	3,562	.	*	103	90	*	*	13,337
6	2,087	8,748	2,011	.	*	23	42	.	*	10,835
7	1,395	7,353	1,328	*	*	39	22	*	.	8,748
8	838	6,467	785	.	*	36	12	*	.	7,305
9	727	5,731	697	*	.	22	*	.	*	6,458
10	255	4,732	242	.	.	*	*	.	.	4,987
11	142	4,173	130	*	*	*	*	.	.	4,315
12	104	3,414	101	.	.	*	.	.	.	3,518
13	73	3,162	69	.	*	*	.	.	*	3,235
14	61	2,639	58	.	.	*	.	.	.	2,700
15	42	2,279	36	.	.	*	.	.	*	2,321
16	24	1,925	22	.	.	.	*	*	.	1,949
17	23	1,678	21	.	*	.	.	.	*	1,701
18	20	1,538	18	.	.	*	.	.	*	1,558
19	13	1,177	12	.	.	*	.	.	.	1,190
20	*	1,023	*	.	*	*	.	.	.	1,033
21	*	939	*	949
22	*	750	*	754
23	*	621	*	.	*	629
24	*	502	*	505
25	*	437	*	443
26	*	354	*	361
27	*	249	*	254
28	*	74	*	77
29	*	81	*	*	83
30	*	52	*	55
31	*	49	*	*	53
32	.	37	37
33	.	23	23
34	*	26	*	*	31
All	335,963	136,136	307,122	193	1,954	10,858	14,907	60	869	472,099

The point prevalent cohorts are determined on December 31 of each calendar year without applying the 60-day stable modality rule.

*Values for cells with ten or fewer patients are suppressed.

" ." Zero values in this cell.

Table D.15

Incident ESRD patients, 2004: by modality & state/territory

	Center hemo	Center self hemo	Home hemo	CAPD	CCPD	Other PD	Uncertain dialysis	Transplant	All
Alabama	1,738	.	*	103	15	*	.	21	1,880
Alaska	90	.	.	23	*	.	.	*	118
Arizona	1,835	.	*	91	16	.	*	29	1,979
Arkansas	874	*	.	62	27	*	*	*	981
California	11,227	*	*	592	159	15	57	191	12,249
Colorado	851	.	.	55	*	.	*	21	936
Connecticut	825	.	*	85	57	*	*	20	991
Delaware	309	.	.	15	*	.	.	*	337
District of Columbia	427	.	*	15	*	.	.	*	450
Florida	5,969	.	90	209	139	17	11	94	6,529
Georgia	2,962	.	*	203	47	*	*	67	3,287
Hawaii	540	.	.	15	.	.	*	*	568
Idaho	196	*	.	50	*	*	.	13	264
Illinois	4,025	.	60	210	101	22	*	122	4,548
Indiana	1,757	.	*	139	20	*	*	59	1,987
Iowa	659	*	*	28	20	.	*	47	761
Kansas	605	.	*	70	*	.	*	15	705
Kentucky	1,250	.	*	82	20	21	*	16	1,397
Louisiana	2,162	.	*	71	15	*	*	25	2,277
Maine	298	.	.	11	*	.	.	16	334
Maryland	2,164	.	*	90	71	*	*	48	2,388
Massachusetts	1,592	.	.	72	46	.	*	45	1,759
Michigan	3,410	.	*	227	36	*	*	102	3,790
Minnesota	1,136	.	*	42	23	*	*	100	1,306
Mississippi	1,164	.	*	93	42	*	.	*	1,314
Missouri	1,767	.	*	118	42	*	*	31	1,971
Montana	159	.	*	17	*	*	.	*	189
Nebraska	474	.	*	13	20	.	*	14	523
Nevada	674	.	.	34	*	.	*	*	723
New Hampshire	259	.	.	19	11	.	*	14	304
New Jersey	3,111	.	*	68	75	*	*	62	3,334
New Mexico	568	.	.	31	19	*	.	*	625
New York	6,597	*	*	156	122	57	*	114	7,065
North Carolina	2,947	.	*	115	126	*	*	45	3,245
North Dakota	143	.	.	18	*	*	*	15	183
Ohio	3,971	.	14	249	63	*	*	98	4,403
Oklahoma	1,090	.	*	58	37	*	*	*	1,207
Oregon	742	.	*	58	14	.	*	18	839
Pennsylvania	4,429	*	*	109	111	*	*	94	4,762
Rhode Island	291	.	.	11	.	.	.	11	313
South Carolina	1,784	.	.	79	64	.	*	24	1,957
South Dakota	197	.	.	*	13	.	*	16	236
Tennessee	1,914	.	*	48	96	.	*	30	2,091
Texas	7,327	.	20	234	206	40	22	91	7,940
Utah	303	*	.	20	*	.	*	26	366
Vermont	103	.	.	*	*	.	.	*	123
Virginia	2,530	.	.	128	43	15	*	49	2,775
Washington	1,263	14	*	81	16	*	*	43	1,422
West Virginia	668	.	.	30	52	*	.	15	775
Wisconsin	1,538	.	.	77	49	*	*	90	1,762
Wyoming	80	.	.	*	*	*	.	*	88
American Samoa	23	23
Guam	68	.	.	*	77
Puerto Rico	1,170	.	*	15	94	*	.	*	1,282
Saipan	22	.	.	*	23
Virgin Islands	47	.	.	*	*	.	.	.	49
Foreign	*	.	.	*	11
Unknown	272	.	*	*	14	*	12	231	543
All	94,606	25	260	4,477	2,209	277	250	2,260	104,364

The incident cohorts are determined at the time of ESRD initiation without applying the 60-day stable modality rule.

*Values for cells with ten or fewer patients are suppressed.

“. “ Zero values in this cell.

Incident ESRD patients for selected years: by state (Table D.e).

Table D.16

Point prevalent ESRD patients, 2004: by modality & state/territory

December 31 point prevalent ESRD patients

	Center hemo	Center self hemo	Home hemo	CAPD	CCPD	Other PD	Uncertain dialysis	Transplant	All
Alabama	6,082	*	24	239	305	.	*	2,253	8,909
Alaska	264	.	*	36	47	.	*	244	595
Arizona	5,627	*	18	179	219	.	12	2,321	8,378
Arkansas	2,399	13	20	174	189	.	*	1,095	3,900
California	37,897	28	95	1,599	1,753	*	135	15,417	56,927
Colorado	2,809	*	*	106	138	.	13	1,724	4,795
Connecticut	2,823	.	*	161	361	.	*	1,402	4,764
Delaware	1,016	.	*	19	42	.	*	503	1,582
District of Columbia	1,742	.	*	32	28	.	*	354	2,163
Florida	17,943	*	207	412	907	*	49	6,969	26,490
Georgia	11,522	*	39	470	556	*	16	3,313	15,918
Hawaii	2,003	.	*	76	42	.	*	558	2,683
Idaho	605	*	*	94	64	.	*	570	1,346
Illinois	13,077	*	312	490	700	11	54	6,948	21,597
Indiana	5,663	.	41	343	272	.	14	2,904	9,237
Iowa	2,056	.	17	58	97	.	*	1,651	3,889
Kansas	1,998	*	17	148	114	.	*	1,052	3,339
Kentucky	3,672	*	26	141	197	*	23	1,714	5,775
Louisiana	6,994	*	22	127	217	.	20	1,905	9,287
Maine	908	.	*	27	52	.	*	591	1,591
Maryland	6,850	.	23	262	362	*	25	3,261	10,785
Massachusetts	4,683	.	32	152	230	.	20	3,074	8,191
Michigan	10,597	*	45	579	387	.	37	5,265	16,911
Minnesota	3,189	*	13	81	134	.	11	3,357	6,786
Mississippi	4,640	*	46	174	286	*	*	1,139	6,294
Missouri	5,624	.	62	283	340	.	*	2,572	8,887
Montana	550	.	*	43	37	.	*	479	1,113
Nebraska	1,321	.	16	47	93	.	*	858	2,337
Nevada	1,768	.	*	82	98	.	*	800	2,760
New Hampshire	693	.	*	37	36	.	*	556	1,328
New Jersey	9,592	*	25	197	363	*	21	3,978	14,184
New Mexico	2,161	.	*	97	128	*	*	808	3,207
New York	21,934	79	114	553	625	*	58	8,081	31,452
North Carolina	10,935	*	38	291	620	*	14	3,361	15,263
North Dakota	381	.	*	39	15	.	*	421	860
Ohio	12,281	*	119	534	553	*	39	5,611	19,141
Oklahoma	3,305	*	18	143	238	.	*	1,364	5,076
Oregon	2,212	.	15	114	160	.	*	1,671	4,178
Pennsylvania	12,827	23	49	308	445	*	58	6,923	20,637
Rhode Island	841	.	*	17	15	*	*	549	1,431
South Carolina	6,280	*	21	167	346	*	*	1,824	8,646
South Dakota	626	.	.	25	46	.	*	458	1,159
Tennessee	6,122	*	37	167	382	.	12	2,637	9,358
Texas	26,242	.	144	629	1,307	*	47	9,011	37,386
Utah	954	*	12	78	26	.	*	1,176	2,254
Vermont	370	.	*	*	15	.	*	267	667
Virginia	8,512	*	69	287	410	*	20	3,415	12,715
Washington	4,050	*	101	171	178	*	*	2,750	7,269
West Virginia	1,648	.	*	69	178	*	*	921	2,825
Wisconsin	4,213	*	21	161	209	.	14	3,581	8,200
Wyoming	243	.	*	15	12	.	*	211	487
American Samoa	91	91
Guam	303	.	.	23	*	.	.	15	343
Puerto Rico	3,336	.	*	67	310	*	*	967	4,698
Saipan	93	.	.	*	.	.	.	12	113
Virgin Islands	157	.	.	*	*	.	.	23	189
Foreign	55	.	*	*	*	.	.	237	296
Unknown	343	.	*	12	16	*	27	1,015	1,417
All	307,122	193	1,954	10,858	14,907	60	869	136,136	472,099

117

on our website & CD

Living ESRD patients on December 31 for selected years: by state (Table D.f.)

The point prevalent cohorts are determined on December 31 of each calendar year without applying the 60-day stable modality rule.

*Values for cells with ten or fewer patients are suppressed.

“.” Zero values in this cell.

d treatment modalities

